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ABSTRACT 
The recent development of canine genomic resources combined with the 
unique phenotypic diversity, population history and breed structure has made 
dogs as exciting large animal models for genetic research. Dogs suffer from 
hundreds of hereditary conditions, many of which are similar to human 
disorders.  
Dog breeds are affected with various hereditary, blinding eye diseases, 
such as cataract, glaucoma, retinal degeneration and lens luxation. Although 
a limited number of genes have been found in some conditions, many more 
remain to be found across breeds. Gene discoveries are important in 
improving the understanding of related disease mechanisms and eye 
physiology, informing breeding programs, and establishing new therapeutic 
models. This study utilized and expanded the remarkable canine resources 
established in Finland to reach new genetic breakthroughs in four different 
canine hereditary vision disorders including retinal degeneration and 
glaucoma in different breeds. 
This study combined basic and clinical research with a network of 
collaborations with breeders and veterinarians to establish clinically relevant 
study cohorts for genetic studies. Genome wide approaches with modern 
sequencing technologies were utilized to map and identify the genetic 
causes. Study cohorts were established for a late-onset progressive retinal 
atrophy (PRA) in the Papillons and Phalénes, for retinopathy in the Swedish 
Vallhunds (SV) and primary closed and open angle glaucoma in Dandie 
Dinmont Terrier (DDT) and Norwegian Elkhounds (NE), respectively.  
Genome wide association study (GWAS) mapped the PRA gene in 
Papillons and Phalénes to canine chromosome 2 (CFA2) and parallel exome 
sequencing identified a breed-specific, recessive mutation (p.Tyr889Serfs*5) 
in the CNGB1 gene with a high carrier frequency (17 %). CNGB1 is 
important for the rod cell function and has been linked to human and murine 
retinal degenerations.  
Clinical studies in the Swedish Vallhund (SV) breed revealed a unique 
type of rod- or RPE-derived multifocal retinal degeneration, with variable 
onset and rate of progression and an incidence of 35 %. The disease was 
mapped to a 6-Mb region on CFA17, with the most highly associated variant 
found in the intron of the MERTK gene with a carrier frequency of almost 60 
%. Quantitative analysis revealed specific upregulation of the gene, 
indicating that the retinopathy is caused by overexpression of MERTK. 
However, further studies are needed to discover to actual mutation. MERTK 
is an excellent candidate gene as it has been associated with similar retinal 
degeneration in rats and humans.  
Glaucoma is related to neurodegeneration mainly of the retinal ganglion 
cells (RGC) and of the optic nerve head. Elevated intra ocular pressure (IOP) 
is a significant risk factor and in dogs, pectinate ligament dysplasia (PLD) is 
commonly associated with glaucoma.  
 A clinical study in DDTs revealed primary closed angle glaucoma (PACG) 
with severe PLD. The GWAS revealed a significant association with a 10-Mb 
region on CFA8, which is syntenic to human chromosome 14 that has been 
associated repeatedly with glaucoma. The identified region includes a large 
number of genes and further studies are required to identify the causative 
mutation in DDTs. 
Finally, primary glaucoma in NEs was mapped to a region on CFA20 and 
a missense mutation, p.A387T, was found in a highly conserved 
metalloprotease domain of the ADAMTS10 gene. This gene has been 
associated with a Weill-Marchesani syndrome (WMS) with ocular and non-
ocular abnormalities in humans and primary open angle glaucoma in the 
Beagle breed. 
Overall, this study brought several breakthroughs and produced new 
insights into the genetics of two blinding ocular diseases in dogs. Gene 
discoveries highlight shared molecular etiologies in canine and human vision 
disorders. This study provides new candidate genes for human conditions 
and has established large animal models for potential therapeutic trials, 
including gene therapy. Genetic findings have enabled the development of 
gene tests for breeding purposes. Furthermore, this study contributes to the 
development of additional clinical, methodological, and sample recruitement 
resources for further genetic studies in many other canine eye disorders 
beyond the addressed conditions. 
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1 REVIEW OF THE LITERATURE 
Purebred dogs have a unique population history. Dogs (Canis lupus 
familiaris) descend from the grey wolf (Canis lupus lupus) and have 
undergone multiple bottlenecks during the domestication process (Fig. 1). 
The timing and location of dog domestication remains controversial. The 
first mitochondrial DNA (mtDNA) based studies suggested the origin to go 
back 100,000 years1, while this estimation was cut to 16,000 years in later 
studies2,3. The fossil evidence of early dog-like canids suggests the 
domestication event to have taken place between 11,000 to 30,000 years 
ago4,5. Thalmann et al. sequenced archeological samples and concluded 
an European origin of dogs. However, their study lacked a reasonable 
representation for the East Asian population6. A recent nuclear DNA 
sequencing study suggested that the domestication took place about 
11,000 to 16,000 years ago with the hunter-gathers rather than 
agriculturists and that the dog-wolf admixture has had an effect in the 
domestication process7. Furthermore, it has been suggested that the 
canine evolution has been parallel with the human evolution8. In addition, 
there were probably multiple domestication events in multiple places that 
led to various domesticated lineages7. Further studies with more 
comprehensive worldwide cohorts including additional archeological 
samples are needed for more accurate conclusions. 
Most of the dog breeds today have been created during the last 100-
400 years with strong founder and breed barrier rule effects, including 
frequent use of popular sires. Breed barrier rules define that only dogs that 
are born from parents of a single specific breed can be registered as 
purebred. Today purebred dogs are divided into more than 400 different 
breeds, representing high phenotypic variability between breeds in 
appearance, behavior and genetic diseases. Breeders have taken 
advantage of spontaneous mutations rather than depending on traditional 
methods of mutagenesis, such as chemicals or retroviral insertions9.  
 
 
 
  
 
Figure 1. The dog has been created from the grey wolf through multiple bottlenecks, from wolf 
to ancient breeds (A) and to modern breeds with variable appearences (B). This 
unique population structure facilitates genetic studies. 
1.1 Unique breed and genome structure facilitates 
gene mapping in dogs 
Every dog breed forms a distinct, genetically isolated population, with 
limited gene flow due to breed barrier rules. In addition, modern breeding 
practices often focusing on a particular appearences present in champions 
modify the genetic structure and diversity of the current breeds.  
The unique population structure makes the dog an excellent model 
animal for genetic research. Limited locus and disease heterogeneity 
accompanies the creation of hundreds of breeds with distinct 
morphological and behavioral features10-12. Within a breed, the genetic 
diversity is limited and characterized by an extensive linkage 
disequilibrium (LD), narrow diversity in haplotypes and broad runs of 
homozygosity10,11. Each breed has a unique recombination history and a 
breed-wise comparison of the genomes reveals varying ancestral 
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haplotypes that can be utilized in gene mapping to narrow down the region 
of interest10,13.  
Along with the creation of dog breeds, the prevalence of hereditary 
disease has increased in different breeds. Over 600 genetic disorders 
have been described in dogs14. Most conditions are breed-specific and the 
phenotypic spectrum is often more limited than in the corresponding 
human conditions. Of the 600 diseases listed in the Online Mendelian 
Inheritance in Animal database (OMIA)14, a causative mutation has been 
found for over 180 conditions. Many conditions diagnosed in dogs are 
analogous to human diseases, such as cataract, diabetes, epilepsy, 
glaucoma, and retinal diseases14. The dog and the human share a 95% 
genetic similarity, which is higher than between humans and rodents. 
Several findigs in dogs have pawed the way to unravel the genetic in 
humans conditions such as cancer15,16, eye disease17, and neurological 
diseases18. Besides similar disorders, pet dogs share their environment 
with humans, becoming exposed to the same environmental factors as 
humans. This is a remarkable contrast to common rodent and fish models, 
which live in highly controlled and pathogen-free laboratory environments.  
1.1.1 Tools and resources for gene mapping in dogs 
 
The availability of genealogical data facilitates canine genetic studies. As 
breed purity necessitates the generation of breed-specific records, dogs 
can often be traced back to several generations. In Finland, the Finnish 
Kennel Club maintains a publicly available database 
(jalostus.kennelliitto.fi/), which contains pedigree and health information, 
including eye examination data, of individual dogs. These records help to 
establish large pedigrees around the affected dogs to model inheritance 
patterns and to design genetic studies.  
The first whole canine genome sequence was published in 2003 based 
on a 1.5x sequence from a Standard poodle19, followed by a higher quality 
7.5x version from a Boxer genome (CanFam1.0). This was later updated 
to CanFam2.0 assembly in 200510. This version, although of good quality, 
included gaps, particularly in the promoter region impacting the annotation 
of the genes. The most recent version (CanFam3.1) based on the whole 
genome sequence from multiple breeds was published in 2012. It covers 
99.8 % of the euchromatin and includes RNA sequences from 10 different 
canine tissues20. The CanFam3.1 genome is an improved version, which 
includes a comprehensive annotation of protein coding and non-coding 
genes, including different isoforms20. The current genome of 2.4 Gb is 
divided into 39 chromosomes and includes approximately 19,900 protein 
coding genes and 29,900 transcripts20.  
Based on the canine genome reference sequence three single 
nucleotide polymorphism (SNP) arrays have been developed for genome 
  
wide case-control association studies (GWAS). SNP is a DNA sequence 
variation that is commonly seen in a population, in which a single 
nucleotide differs between individuals. GWAS analysis is performed by 
comparing allele frequencies of each SNP. The aim is to find statistically 
significant differences between the case and control group of choice. The 
first SNP array was developed by Affymetrix and included 50,000 SNPs, 
followed by two Illumina arrays, Illumina Canine SNP20 BeadChip, 
including 22,000 markers, and the current state-of-the-art Illumina 
CanineHD BeadChip with 173,000 SNPs. Extensive LD within breeds 
makes it possible to test the genome with fewer SNPs than required in 
human studies10. In dogs multiple loci of large effect have been described 
for several phenotypes using GWAS9. However, extensive LD within 
breeds makes fine mapping more difficult, as many markers co-segregate 
with the actual causal variant9.  
Besides SNP arrays, the advanced next generation sequencing (NGS) 
approaches can be applied to canines. Both the targeted and whole 
exome sequencing approaches are based on probes designed for the 
canine reference sequence. In exome sequencing specific probes are 
designed to target the protein coding genes, which are selectively 
captured from the whole genome and sequenced. Two specific platforms 
are available for canine whole exome sequencing. The first exome capture 
kit was developed by Agilent (Agilent, Santa Clara, CA, USA) based on the 
CanFam2.0 reference sequence. The capture includes a 54 Mb design 
that covers the Ensembl (www.ensembl.org) and RefSeq Genes from the 
UCSC track (genome.ucsc.edu), human protein alignments and spliced 
ESTs that lie outside Ensembl. Another exome capture kit, SeqCap EZ 
Library, is offered by Roche Nimblegen and is based on a solution-based 
capture method and a custom design of approximately 50 Mb, based on 
the CanFam3.1 reference sequence designed in the Broad Institute 
(www.broadinstitute.org). 
The disadvantage of NGS relates to more complicated approaches in 
data qualite, analysis and management. Millions of SNPs and indels are 
produced from the variant calling and the number of possible candidate 
variants may be very high. Especially in more complex phenotypes where 
the causative variant may lie outside the protein coding regions. However, 
the more dogs are whole genome and exome sequenced and the data, 
with good coverage, made publicly available, the more efficient filtering 
may be applied to the data to decrease the number of potential causative 
variants. 
These modern tools have been utilized in this study to unravel genetic 
causes in canine vision disorders. 
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1.2 The eye 
The eye is a very unique sensory organ responsible for vision (Fig. 2). It is 
designed to function in a camera like fashion and to absorb and reflect 
light21. The light is directed to the retina and electro-chemical impulses are 
sent trough complex neural pathways via the optic nerve to the visual 
cortex, where nerve signal is conferred to a visual image21.  
Vertebrates have complex eyes of different shapes and colors. Animals 
with binocular vision, especially predators, have eyes that move 
simultaneously to improve depth perception22. Animals with monocular 
vision have eyes that are used separately to see and are positioned widely 
apart as possible22. In addition different species show huge variation in 
such aspects of vision as visual acuity, color vision, pigmentation, light 
sensitivity, and the numbers and types of photoreceptor cells in the 
retina22. 
 The normal structures of the canine eye and the diseases affecting the 
various parts of the eye are probably the best described and characterized 
in dogs among model animals used in genetic research17. The eye is a 
very accessible organ and non-invasive techniques can be used to 
diagnose and treat abnormalities affecting different parts of the eye17. 
However, the eye is also a very sensitive organ and diseases in other 
parts of the body may cause abnormalities in the eye. For example, 
diabetes may cause diabetic retinopathy, secondary cataract, and 
glaucoma23. Similarly, inflammation may cause retinal and lens alterations 
and glaucoma24,25. 
Hereditary eye diseases affect primarily a certain part of the eye, where 
diseases of the retina and lens are the most prevalent17.  For example, 
retinal degenerations originate from the abnormal function and structure of 
particular retinal cells26. In cataracts, abnormalities are detected in the lens 
structure27 and primary lens luxation is due to the deterioration of the lens 
ligaments that hold the lens in its position rather than actual disease of the 
lens28. Furthermore, glaucoma is characterized by neurodegeneration of 
the RGCs and changes in the optic nerve head29. Moreover, many other 
diseases affecting other parts of the eye are diagnosed. However, many 
eye diseases lead to secondary manifestations in other parts of the eye30. 
As this study focused on the genetics of retinal degeneration and 
glaucoma the specific characteristics of the eye that are affected will be 
discussed in more detail in the following chapters. These characteristics 
include the structure of the retina, the visual cycle, which is related to the 
function of the retina, and the iridocorneal angle and aqueous humor flow 
that are related to the development of glaucoma.  
 
 
 
  
Figure 2. A schematic structure of the eye and its functional components (modified from 
virtualmedicalcenter.com). 
1.3 Retina  
The visual process is generated through multiple biochemical and 
photochemical reactions21. These light sensitive reactions take place in the 
retina, which is a highly organized structure and part of the central nervous 
system (Fig. 3)21. The retina is a complex tissue in the back of the eye. 
Newborn canines have an undeveloped retina that matures during a 
postnatal period at 3-6 weeks31. The structure of the canine and human 
retina is similar, except that humans are born with a more developed 
retina. In addition, dogs have a light-reflecting area called tapetum lucidum 
and a heavily pigmented choroid but lack the macula and fovea32. 
However, dogs have a fovea-like area called area centralis, which is 
constructed with uniquely packed cone photoreceptors33. 
The retina can be divided into tapetal fundus backed by brightly 
reflecting tapetum lucidum and non-tapetal fundus32. The optic disc is in a 
fixed position in the area where the optic nerve exists the orbit22. The color 
of the retina varies greatly between breeds and in some breeds is related 
to the coat color (Fig. 4)34. The color of the retina does not appear to have 
an effect on the eye function34,35. 
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Figure 3. A) A schematic description of the retinal layers (modified from Koeppen & Stanton: 
Berne and Levy Physiology, 6th Edition).  B) Histology of the normal canine retina 
shows clearly the different layers of the retina (photo courtesy of Professor Andras 
Komáromy). In retinal degeneration the photoreceptors, rod and cones, are typically 
affected. Glaucoma is cause by degeneration of the retinal ganglion cells (RGC). 
The neuroretina is supported by the retinal pigment epithelium (RPE) 
and the Müller glial cells. The latter cell types also provide important 
metabolites to the photoreceptors and act as scavengers by removing 
used photopigments. There are six different types of neuronal cells in the 
retina: ganglion, amacrine, bipolar, horizontal, interplexiform, and 
photoreceptor cells. All are involved in light-processing (Fig. 3)21. 
Traditionally, the retina is divided into 10 different layers: retinal pigment 
epithelium (RPE), photoreceptor layer, external limiting membrane, outer 
nuclear layer, outer plexiform layer, inner nuclear layer, inner plexiform 
layer, ganglion cell layer, nerve fibre layer and internal limiting membrane 
(Fig. 3)21.  
Photoreceptor cells comprise a complex layer of specialized cells, rods 
and cones. Rods function in low light and are inactivated by constant 
bright light21,22. Cone cells function during daylight, adapt rapidly and need 
strong light stimulus to react21,22. They do not function in dim light21,22. The 
photoreceptor cell can be subdivided into the following parts; the inner and 
outer segments, nucleus and the synaptic structure. The inner and outer 
segments are connected by a connecting cilium originating from the basal 
body in the inner segment21. 
The optic nerve head appears as cream or pink colored mainly circular 
area in the fundus (Fig. 4)21. It is responsible for the transfer of light 
induced signals from the retina to the visual cortex in the brain36. The optic 
nerve is mainly composed of axons of the RGC36 and includes four 
regions, the RGCs, the nerve fibre layer (NFL), the optic nerve head 
(ONH) and the intralaminar region within the sclera (Figs. 2 and 4)21.  
 
  
 
Figure 4. A large variation is detected in the color of normal canine retina between different 
breeds (photos DVM Sari Jalomäki and DVM Kaisa Wickström). The optic nerve 
head is marked with an arrow. 
1.4 The iridocorneal angle and aqueous humor flow 
The iridocorneal angle (ICA) is formed circumferentially by the peripheral 
parts of the iris and cornea (Figs. 2 and 5)21. The internal boundary of the 
ICA is formed by pectinate ligaments (PL) structure that is not present in 
the human eye (Fig. 5)37. The PL is presented as a pillar of tissue, which 
projects from the base of the iris to the peripheral Descemet’s membrane 
and provides support for the iris toward the posterior cornea37. The normal 
pectinate strands are thin to stout strands bridging the iridocorneal angle 
from the iris base to the periphery of the cornea38. Most of the strands are 
single, although some may be connected38. Normal PLs do not form an 
anatomic barrier to aqueous humor flow37. Behind the PL is a matrix of 
loose tissue strands, the trabecular meshwork, which consists of 
crisscrossing collagen cords21. The space between PLs is filled with 
glycosaminoglycans (GAG)37, which form the integral component of 
trabeculae within the ICA. GAGs appear to regulate IOP by their state of 
polymerization. Abnormalities in the PLs may cause the release or 
abnormal polymerization of GAGs21. 
Aqueous humor flows from the posterior chamber through the pupil into 
the anterior chamber, and to the drainage angle (Fig. 5)21. It flows between 
the PLs and into the trabecular meshwork. The aqueous humor leaves the 
eye either through the corneoscleral trabecular meshwork or the ciliary 
body and anterior uvea21. When the aqueous humor flow production by the 
ciliary body and drainage through the ICA is in balance it creates a normal 
IOP, helping to maintain the shape of the eye21. 
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Figure 5. The schematic structure of the iridocorneal angle (ICA). The aqueous humor flows 
from the posterior into the anterior chamber, and to the drainage angle. It flows 
between the pectinate ligaments and into the trabecular meshwork (picture modified 
from Holger Funk: www.shiba-dog.de/shiba-klub/glaukom-en.htm). In closed angle 
glaucoma abnormalities in the pectinate ligaments lead to obstruction of the 
aqueous humor and collabse of the ICA, which further leads to elevated IOP.  
1.5 Visual cycle 
The visual cycle occurs mainly in the RPE, Müller cells, and in the 
photoreceptors39. Two important pathways, the retinoid cycle and the 
phototransduction cascade, are involved in vision (Fig. 6)39. The rod 
dominated retinoid cycle starts with the absorption of light by rhodopsin39. 
This causes 11-cis-retinal to bind as protonated Schiff base to rhodopsin 
and isomerize to all-trans-retinal, producing inactive protein opsin39. It is 
then detached from rhodopsin in photoreceptor cells and enzymatically 
transformed by retinol dehydrogenase (RDH) to all-trans-retinol (vitamin A) 
in the rod cells cells40. Vitamin A is then transported from photoreceptors 
into the RPE by retinol binding protein (IRBP)40,41 or by ABCA4 
transporter42. After this, it is transferred to lecithin retinol acyl transferase 
(LRAT)43,44 by cellular retinol-binding protein (CRBP). LRAT is esterified 
and further hydrolyzed and isomerized by retinal pigment epithelium 65 
(RPE65) and other enzymes and retinoid binding proteins to produce 11-
cis-retinol39,45. The light sensitive 11-cis-retinol is oxidized to 11-cis-retinal 
by cis-specific retinol dehydrogenase (cis-RDH5). This cascade is 
chaperoned by cellular retinaldehyde binding protein (CRALBP)39,45. The 
11-cis-retinal is then taken up by CRALBP and transported to the apical 
membrane of the RPE and transferred back to the photoreceptor outer 
segment. It is then reattached to opsin to form functional rhodopsin (Fig. 
5)39,45. 
However, the retinoid cascade is more complex and alternate pathways 
have been reported46,47. In addition, additional enzymes have been 
  
identified that play a role in the visual cycle48 and in the mouse the 
presence of other cis-retinals has been shown48,49.   
The phototransduction cascade functions in the convertion of light 
stimuli to neuronal signal (Fig. 6). The cascade is activated by the 
absorption of light by the visual pigment which activates G-protein 
signaling cascade50,51. The heterotrimeric G-protein transducing (Gt) is 
bound to rhodopsin (R*) and this in turn activates phospodiesterase (PDE) 
to PDE**52. PDE** hydrolyzes intracellular cGMP52. This leads to the 
closure of the cGMP-gated ion channels in the plasma membrane and the 
subsequent reduction in intracellular calcium (Ca2+)53. This leads to 
hyperpolarization of the photoreceptors and further to neuronal 
signalling53. The decrease in Ca2+ concentration induces a conformation 
change in recoverin (Rec) and its dissociation from rhodopsin kinase 
(RK)54. After that the kinase can bind and multiply phosphorylated 
rhodopsin54.  The increased rhodopsin level decreases the binding 
affinities of RK and Gt and increases the affinity of Arrestin (Arr) for 
rhodopsin54. The decrease in Ca2+ also triggers the activity of two 
guanylate cyclase activating proteins (GCAPs). This causes guanylate 
cyclases (GCs) to synthesize cGMP leading to the re-opening of the 
cGMP-gated ion channels and a return to the dark circulating current (Fig. 
6)54. 
Traditionally, the visual cycle has been studied in the rod OS and RPE, 
but cones are thought to have a unique visual cycle55. Cones are 
specialized to function in day light, when the amount of 11-cis-retinal 
increases due to constant light55. The cone cycle is believed to take place 
in the photoreceptors and the Müller glia cells55. The cones regenerate 11-
cis-retinal in the Müller cells from 11-cis-retinol, which is formed from all-
trans-retinol in the photoreceptors55,56. All-trans-retinol is transported to the 
cone inner segment and oxidized to 11-cis-retinal to form visual 
pigment55,56. 
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Figure 6. Two important pathways, the retinoid cycle (A) and the phototransduction cascade 
(B), are involved in visual processing. A) The retinoid cycle recycles the light-
absorbing photon and converts 11-cis-retinal bound to opsin (Rho) into all-trans-
retinal. All-trans-retinal is reduced by retinol dehydrogenase (RDH) to all-trans-
retinol. All-trans-retinol is exported to the RPE and converted to 11-cis-retinol by 
RPE65, and oxidized to 11-cis-retinal by NAD and a cis-specific retinol 
dehydrogenase (cis-RDH). 11-cis-retinal is exported back to the OS to opsin. 
(CRALBP cellular retinaldehyde-binding protein, CRBP cellular retinol-binding 
protein, IRBP interphotoreceptor matrix retinoidbinding protein). B) The 
phototransduction cascade converts light stimuli to electrical signal. Activated opsin 
(R*) activates transducin (G) to G* which in turn activates phosphodiesterase (PDE) 
to PDE**. PDE** hydrolyzes cGMP, reducing its cytoplasmic concentration. This 
results in closure of cGMP-gated CNG-channels. This causes hyperpolarization of 
the photoreceptors leading to signals sent to the downstream neurons. Mutations in 
several genes that function in the visual cycle have been associated with retinal 
degenerations. Mutations in genes important for visual pathways have been 
associated with abnormal vision including RPE65, RHO, and genes such as CNGB1 
and CNGB3, important in the CNG channel formation. The figure is modified from 
(Nawrot et al. 200657 and Pugh 199950). 
 
  
1.6 Canine vision disorders 
Different breed clubs in many countries have obligatory ophthalmoscopical 
screenings for dogs used for breeding. This helps to identify, follow and 
study vision disorders in dogs. Finland uses the European College of 
Veterinary Ophthalmology (ECVO) scheme (www.ecvo.org), which has 
been implemented in ten European countries. Over 20,000 dogs are eye 
examined yearly in Finland by ECVO panelists, which is more than 
elsewhere in Scandinavia (personal communication with DVM Kaisa 
Wickström). The examined dog receives a certificate, which is valid from 
one to three years depending on the breed´s eye scheme (ECVO). The 
results are stored in an open access database maintained by the Finnish 
Kennel Club (jalostus.kennelliitto.fi/). This publicly available database, 
athough not fully accurate, is a valuable resource for research as affected 
dogs can be found from the database and the owners can be contacted to 
obtain samples and additional information on the dogs and the diseases. 
Furthermore, there are several private research-orientated ECVO 
panelists interested in collaborating with genetic research and ready 
prepared to provide samples and essential clinical data for the genetic 
studies.  
Dogs are diagnosed with several inherited eye diseases affecting 
different parts of the eye, such as the lens, retina, ICA, cornea, vitreous 
etc. The Online Mendelian Inheritance in Animal database (OMIA) lists 57 
different hereditary eye diseases in dogs14, with cataract being the most 
frequent ocular disease diagnosed in dog58, followed by retinal 
degenerations and glaucoma, which affect a large number of pure bred 
dogs59. 
Many eye diseases are recessively inherited, although dominant, X-
linked and complex mode of inheritance have also been described14. 
Inbreeding is likely to have enriched recessive mutations, and as many 
eye diseases are late-onset they may not have been selected against, 
since they are only diagnosed after the dog has been used for breeding.  
The following chapters will review two neurodegenerative eye 
conditions, relevant for the study, retinal degeneration and glaucoma, in 
more detail.   
1.7 Canine degenerative retinal diseases 
Many different breeds are affected with different types of degenerative 
retinal diseases affecting different parts of the retina (OMIA)14. The 
spontaneous canine retinal diseases are probably one of the best-
described and studied diseases, both clinically and genetically. Canine 
retinal degenerations form a heterogeneous group of disorders with breed-
specific phenotypes observed even among those diseases that arise from 
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the same mutation (Table 1). On the other hand, similar phenotypes 
caused by distinct mutations in different genes are diagnosed, in various 
breeds17. For example, in the Golden Retriever there are at least three 
genetically different types of retinal degeneration caused by different 
genes61-63.  While the involved genes vary, the apoptotic cell death 
appears as a common pathway in retinal diseases64, resulting from cell 
death pathway activation, which is mutation specific, and leading to the 
degeneration and death of photoreceptors and eventual blindness65. Many 
retinal diseases remain to be clinically and genetically characterized 
across breeds. 
Retinal degenerations can be classified in different ways, such as 
according to age onset, the affected part of the retina or whether the 
disease is progressive or stationary. In addition, other developmental 
disorders may affect the retina, such as micropthalmia21 and Collie eye 
anomaly (CEA)66.   
The most typical type of canine retinal degeneration is a progressive 
retinal atrophy (PRA) that is primary a rod degeneration. Most PRAs are 
recessively inherited although some dominant60 and X-linked67-69 forms are 
also known. In PRA, the light sensitive rod photoreceptor cells degenerate 
first, resulting in a visual impairment in dim light with night blindness59. 
Commonly, as the disease progresses, the cone cells become also 
affected leading to a complete loss of vision59. However, the rate of 
progression varies significantly in individual dogs and in different breeds, 
suggesting modulatory genetic or environmental factors59.  
Ophthalmoscopically the clinical signs in PRA include bilateral tapetal 
hypo-reflectivity, and later hyper-reflectivity, which is caused by retinal 
thinning. There is also retinal vascular attenuation, sometimes pigmentary 
changes and pale optic disc59. Clinically PRA is diagnosed on the basis of 
the specific fundus changes and an abnormal electroretinogram (ERG). If 
available, optical coherence tomography (OCT) is also used. ERG detects 
the electric responses from the retina while the OCT is a three-
dimensional visualization method. Clinically it is challencing to distinguish 
types of PRAs that are genetically different as the clinical signs in the 
retina and ERG responses are usually similar. This highlights the value of 
genetic research and genetic testing for providing differential diagnoses. 
In addition to progressive retinal diseases, stationary types of retinal 
degenerations and primary cone diseases are also diagnosed in dogs 
(Tables 4 and 5). 
1.7.1 Early-Onset Progressive Retinal Atrophy (PRA) 
 
Early-onset retinal degenerations manifest between 2-6 weeks, during the 
postnatal differentiation period26. The retinal development is abnormal or 
  
arrested and the disease progression is usually quite rapid leading to end-
stage disease (Table 1)26. 
Irish Setters are affected with an early-onset degeneration named 
RCD1, where the rod photoreceptor development is arrested, leading to 
the loss of almost all rod cells by 5 months of age26. The affected dogs 
have less rod outer segment material, short inner segments and fewer 
visual cells70. As the disease progresses cone cells with a broad inner 
segment and a short and abnormal outer segment are detected70. Aguirre 
et al. showed that affected dogs have abnormal cyclic GMP metabolism 
and that the deficiency in cyclic GMP-phosphodiesterase activity impairs 
their ability to hydrolyze cyclic GMP in the retina leading to accumulation 
of GMP-phosphodiesterase in the retina70,71. A mutation in the rod cGMP-
specific 3',5'-cyclic phosphodiesterase subunit beta (PDE6B) has been 
found in the affected dogs72. 
PDE6B encodes the β subunit of rod photoreceptor cyclic guanosine 
monophosphate (cGMP)-phosphodiesterase (PDE), which is a vital 
enzyme of the visual phototransduction cascade. The PDE6 enzyme 
consists of an α and β subunit, and two γ subunits. The activated cGMP-
PDE complex leads to a reduced intracellular concentration of cGMP and 
the closure of the cGMP-gated cation channels on rod cells leading to a 
neural response to light stimulus73,74.  
In addition to Irish Setters, other mutations in PDE6B have been found 
in the Sloughi75 and American Staffordshire Terrier76. The Sloughi have a 
later onset disease with visual abnormalities appearing at around 2 years 
of age 75. In contrast, the retinal disease in the American Staffordshire 
Terrier is very similar to the disease seen in Irish Setters76,77. The PDE6B 
gene has also been associated with retinal degeneration in mice78 and 
humans79 with a similar phenotype to dogs. The mice are affected with a 
complete loss of rod cells by postnatal day 20 with an increased level of 
cGMP78.  
Another guanosine monophosphate (cGMP)-phosphodiesterase (PDE) 
related mutation has been found in the α-subunit. A mutation in the 
phosphodiesterase 6A, cGMP-specific, rod, alpha (PDE6A), termed RCD3 
has been found in the Cardigan Welsh Corgi80. The affected dogs have 
clinical signs typical of an early-onset PRA starting at 6 to 16 weeks and 
leading to blindness at one year of age81. Some dogs may have limited 
central vision until the age of 3 to 4 years81. 
A more detailed clinical study was performed by Tuntivanich et al. who 
showed that the affected dogs have abnormal rod cell outer segment 
development and reduced light adapted responses82. The cone cells are 
relative well preserved82. The retinas lack the PDE6A, but also other PDE6 
complex subunits leading to a lack of PDE6 enzymatic activity82. In 
addition to dogs the PDE6A mutation has been reported to cause retinal 
degeneration in mice with increased level of cGMP83 and in humans with a 
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severe, early-onset retinal disease84-89. This indicates that the PDE6A is a 
vital part of the PDE6 enzyme. 
Another type of RCD, termed RCD2, has been described in the Rough 
and Smooth Collies90. The affected dogs have night blindness at the age 
of 6 weeks and ERG-confirmed retinal dysfunction already around 16 days 
of age90. The photoreceptor outer segments are underdeveloped and 
disappear completely during disease progression90. The disease affects 
both rod and cone cells during the postnatal development period, although 
the cone cells degenerate more slowly90. An unusual observation 
compared to other PRAs, is the accumulation of lamellar bodies in the 
RPE, hypothesized to be of mitochondrial origin, at a very early age91. 
RCD2 is caused by a repeat sequence insertion in the retinal degeneration 
3 (RD3) gene leading to an extended, abnormal reading frame92. 
The RD3 gene is highly expressed in photoreceptor cells and rd3 
defective mice show a rapid loss of these cells and outer nuclear layers 
during the second postnatal week93,94. In humans multiple different 
mutations have been found in the RD3 gene causing early-onset, severe 
RP and Leber congenital amaurosis (LCA)95. 
An RCD1- and RCD3-like disease has been described in the 
Norwegian Elkhound with initial night blindness and total vision loss at 12 
to 18 months of age96. Both the structural and functional postnatal 
development of photoreceptor cells appear abnormal96. Although, the 
inner- and outer segments of photoreceptors develop normally, the 
synaptical terminals of rods and cones remain underdeveloped and result 
in incoordinated function96. A SINE insertion was found in the 
serine/threonine kinase 38-like (STK38L) gene in the affected NEs97. The 
gene belongs to a nodal-related subclass of AGC protein kinases, which 
are involved in cell division control and cell morphogenesis also in 
neurons98. Berta et al. studied STK38L in the canine retina and concluded 
that defective photoreceptors undergo cell death or proliferation generating 
a new class of hybrid rod/S-cone photoreceptors suggesting a role for 
STK38L in the control of cell division and photoreceptor morphogenesis99. 
Another type of early-onset PRA has been described in the Miniature 
Schnauzer (MS). Although the clinical signs become visible at dogs 
around 4 years of age, histologically the disease can be diagnosed already 
at the end of the postnatal developmental period and affects both rod and 
cone cells100. Originally the disease was thought to be caused by a 
mutation in the phosducin (PDC) but this was excluded by further 
studies100. The MS PRA has been named Type-A PRA and a gene test is 
offered for an unpublished mutation, to test dogs (www.optigen.com). 
However, Type-A disease only causes a minority of the cases in the 
Miniature Schnauzer and a yet to be identified gene is responsible for the 
other disease types (www.optigen.com). 
 
 
  
Table 1. Several breeds are affected with an early-onset PRA. 
Gene Breed CFA 
Mode of 
inheritance 
Phenotype* 
Age of 
diagnosis 
Mutation 
found in 
humans  
Ref 
 
Miniature 
Schnauzer 
 recessive 
PRs affected at the 
end of the 
postnatal period 
congenital  100 
PDE6B 
Irish Setter, 
Sloughi, 
American 
Staffordshire 
Terrier 
3 recessive 
abnormal rods, 
short IS, fewer 
visul cells, 
accumulation of 
GMP 
congenital ✓ 
72, 
75, 
76, 
93 
 
PDE6A 
Cardigan 
Welsh Corgi 
4 recessive 
abnormal rod OS 
and light adapted 
responses, cones 
preserved 
6-16 
weeks 
✓ 
80, 
84-
89 
 
RD3 
Rough and 
Smooth 
Collie 
7 recessive 
OS 
underdeveloped 
and disappear 
completely 
16d-6 
weeks 
✓ 
92, 
95 
 
STK38L 
 
Norwegian 
Elkhound 
27 recessive 
abnormal 
structural, 
functional 
postnatal 
development 
12-18 mo  97 
*(PR, photoreceptor) 
1.7.2 Late-onset PRA 
 
Late-onset PRAs are usually diagnosed in two-to-three-year-old dogs, 
although variation is quite extensive across breeds (Table 2)17. The retinal 
changes are diagnosed after the retinal development and maturation 
period, and the disease progression is slower than in early-onset 
disease17. 
One of the most common mutations causing late-onset PRA was found 
in the progressive rod cone degeneration (PRCD) gene63. In PRCD-PRA, 
the normal postnatal retinal development is followed by a significant 
reduction in rod outer segment (ROS) renewal, and the development of 
early disease in the rod outer segments. A complete photoreceptor loss 
occurs late in the disease101,102. 
The PRCD-PRA was originally characterized in Miniature Poodles101 
and the PRCD locus was mapped to CFA9 using linkage analysis103. The 
locus was further narrowed down103,104 and a recessively inherited 
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mutation in the PRCD gene was identified63. Today the PRCD mutation 
has been found from more than 30 breeds 
(www.optigen.com/opt9_test_prcd_pra.html). 
PRCD is important in the maintenance of the rod photoreceptor 
function and structure and it is expressed in the photoreceptor disc and in 
the outer segments of both rod and cone cells105. Three mutations in 
PRCD have also been found in human patients with retinitis 
pigmentosa63,106,107. The patients are affected with a recessive RP with 
typical clinical signs of the disease, including vessel attenuation and 
pigmentation106, similar to the canine PRCD model63. 
Another recessively inherited late-onset PRA has been diagnosed in 
the Schapendoes breed108. The affected dogs show initial night blindness 
at 2-5 years of age followed by a loss of day vision as the disease 
progresses108. Histologically the outer retina with the photoreceptor layer 
and the outer nuclear layer are affected108. The inner retina shows 
reduced inner nuclear and inner plexiform layers, whereas the ganglion 
cell layer appears normal108. The causative mutation was found from the 
coiled-coil domain containing 66 (CCDC66) gene109. 
CCDC66 expression in the retina is prominent in the inner segments of 
photoreceptor cells and at a lower level in the external plexiform and 
ganglion cell layers109. CCDC66 has been shown to cause retinal 
degeneration in a mouse model110. The Ccdc66 mutant mice show 
degeneration of photoreceptors already at 13 days of age, followed by a 
slow, progressive retinal degeneration110. In the wild-type mouse, the 
Ccdc66 protein is present at highest levels after birth, followed by a 
decline until adulthood, suggesting a crucial role in the early 
development110. This supports the proposed role of CCDC66 gene as a 
causative factor for early, slow progressive rod–cone dysplasia110. 
Other late-onset, recessive PRA mutations have been found in Golden 
Retrievers. These include mutations in PRCD, in a solute carrier anion 
exchanger (SLC4A3)61 and tetratricopeptide repeat domain 8 (TTC8)62 
genes. SLC4A3 explains the majority of PRA cases while the PRCD and 
TTC8 mutations account for 39 % of the affected dogs62. 
The SLC4A3 gene mediates the intracellular pH via Cl‾/HCO3‾ 
exchange in cell membranes111. This anion exchanger is expressed in the 
Müller and horizontal cells of the retina112 and in the retinal pigment 
epithelium (RPE) cells113. SLC4A3 also contributes to the removal of 
photoreceptor-generated CO2 waste, which contributes to the 
maintainance of the acid-balance in the inner retina114. A defective 
SLC4A3 causes deregulation in pH mechanism and a selective inner 
retina defect followed by photoreceptor degeneration in mice114. 
The TTC8 gene is part of the BBSome complex, which is composed of 
seven Bardet–Biedl syndrome proteins, functions at the ciliary membrane 
and is thought to play a role in ciliogenesis115. TTC8 is expressed in the 
  
connecting cilium in the retina115. It has been associated with Bardet-Biedl 
syndrome and non-syndromic RP in humans116,117. 
Although several late-onset PRAs are diagnosed in Golden Retrievers, 
it has not been shown which part of the retina is primarily affected in PRAs 
caused by SLC4A3 and TTC8. The symptoms begin with night blindness 
indicating a rod mediated disease. However, it is possible that the primary 
degeneration begins from some other part of the retina and rods are 
secondarily degenerated. The SLC4A3 and TTC8 genes explain a majority 
of the PRA cases, but neither are known to be expressed in rod cells, 
which may indicate that the primary tissue is indeed some other layer of 
the retina. 
In addition to Golden Retrievers, Gordon and Irish Setters are affected 
with a recessive, very late-onset PRA in which the average age of 
diagnosis is around 10 years118,119. The affected Gordons with the late-
onset disease present initial night blindness prior to extensive visual 
impairment, which indicates a rod-mediated degeneration although this 
has not been histologically confirmed118. 
The causative mutation has been mapped to chromosome 2 open 
reading frame 71 (C2orf71) gene118. C2orf71 is highly expressed in the 
eye and is localized to photoreceptors, specifically the outer segment and 
connecting cilium120. Mutations in C2orf71 in human RP patients have also 
been identified120-123. In addition, Irish Red and White Setters can also be 
diagnosed with an early-onset PRA caused by the PDE6B gene72. 
More recently a SINE insertion in a family with sequence similarity 161, 
member A (FAM161A) gene was suggested to be the cause of the late-
onset PRA in Tibetan Spaniels and Tibetan Terriers124. Both breeds are 
affected with a typical type of PRA124,125. The age of onset is around 4-5 
years, the disease in recessively inherited and bilateral with typical retinal 
lesions diagnosed124,125. However, the disease progresses rapidly leading 
to the loss of vision in a couple of years from the initial diagnosis124,125. 
FAM161A is expressed in several tissues including the retina126 and it 
has been located in the inner photoreceptor segment, connecting cilium 
and in the centriole of photoreceptor cells127,128. In humans mutations in 
FAM161A have been associated with recessive RP126,129-131 and in a 
Fam161a mouse model, the mice present a progressive loss of 
photoreceptors and severely impaired vision132. The migroglia show 
alterations to their morphology and have migrated to the outer retina132. 
The affected mice show accumulation of rhodopsin in the photoreceptor 
inner segment132. However, the retinal architecture is fairly well preserved, 
although the connecting cilium length and the spreading of the 
microtubules are reduced132.   
A S-antigen (SAG) mutation was also recently associated with PRA in 
Basenjis with initial visual loss in dim light, which gradually progressed to 
total blindness132. The initial visual loss affects the peripheral visual field, 
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but the affected dogs retain adequate forward daylight vision for many 
years, sometimes for their entire natural life133. 
The S-antigen or arrestin gene is expressed in the rod outer segment 
and belongs to a family of inhibitory proteins that bind tyrosine-
phosphorylated receptors to block their interaction with specific G-proteins 
to terminate a signal chain134. In the retina, arrestin binds to activated 
rhodopsin in the rod outer segments134 to slow G-protein binding and 
quenches rhodopsin activity135. In humans, mutations in this gene have 
been associated with Oguchi disease, a rare form of autosomal recessive 
stationary night blindness (OMIM 613411, 258100) and RP136-38. 
In addition to several recessively inherited retinal degenerations, a 
dominant form of PRA has been diagnosed in the English Mastiff60 and its 
relative breed, Bull Mastiff139. The clinical features of the Mastiff PRA 
include a normal ERG function until the age of three to six months60. After 
this, the ERG responses become abnormal and the disease progression is 
detected as a focal photoreceptor degeneration60. A unique characteristic 
of this phenotype is a dose-response between light exposure and the early 
alterations in the retina. The higher light dose causes a more rapid loss of 
retinal neurons60.   
The causative mutation has been found in the rhodopsin (RHO) 
gene60. Rhodopsin functions as part of the visual cycle where 11-cis-
retinal is converted into all-trans-retinal and facilitates the binding of 
transducin to rhodopsin, subsequently generating an electrical signal via 
channels gated by cyclic guanosine monophosphate140,141. Rhodopsin is 
light-sensitive and light induces the cis-to-trans conversion, which further 
increases the amount of active rhodopsin140,141. Active rhodopsin acts as a 
guanine nucleotide exchange factor for transducing140,141. 
In humans, over 100 mutations have been found in RHO142. The RHO 
mutations cause two distinct phenotypes, an early-onset disorder with a 
rapid loss of rod cells across the retina, and the second phenotype with 
normal rod vision early in the life with degeneration slowly spreading from 
focal retinal regions142-144. Abnormally slow rod recovery after bright light 
exposure is associated with the phenotype143,144.  
1.7.3 Late-onset PRA in Papillon and Phaléne breeds 
 
The Papillon breed is affected with an autosomal recessive, late-onset 
PRA with a mean onset age of 5.6 years145. However, variability is 
detected in the onset possibly due to genetic heterogeneity or 
environmental factors146. Based on the electroretinogram (ERG) 
recordings, affected dogs have a primary loss of rod photoreceptor cells, 
followed by the subsequent loss of cone cell function147,148 with thinning of 
the outer nuclear layer with age, tapetal reflectivity and retinal vascular 
attenuation followed by pigment migration146. The first clinical sign is the 
  
loss of night vision145. The disease progress very slowly and the affected 
dogs seem to be visually normal throughout their life, as the cone function 
is fairly well preserved147,148. 
The American Kennel Club registers only a single Papillon breed, but in 
Europe the breed is separated into two different breeds, Papillon and 
Phalène (Fig. 7). The separation is based on the ear morphology, with 
Papillons having bricked ears while Phalènes have more low set ears (Fig. 
7). The littermates are registered on the basis on their ears and because 
of this the breed is expected to have a similar genetic background. 
Moreover, since affected dogs with a similar PRA have been found in both 
forms, it is reasonable to hypothesize that the genetic cause of PRA is 
also shared. The genetic cause, however, has remained unknown until this 
study. 
 
 
Figure 7. Papillon (A) and Phaléne (B) breeds are separated only by their ear morphology in 
Europe. Both forms suffer from a PRA which genetic cause was unknown prior to 
this study. 
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Table 2. Several late-onset PRAs are caused by various genes in dogs.  
Gene Breed CFA Mode of 
inheritance Phenotype* 
Age of 
diagnosis 
Mutation 
found in 
humans  
Ref 
RHO 
English and 
Bull Mastiff 
20 dominant 
PR loss, dose-
response to 
light 
3-6 mo ✓ 
60, 
142 
PRCR 
Multiple 
breeds 
9 recessive 
ROS reduction, 
PR loss at late 
stage 
variable ✓ 63 
CCDC66 Schapendoes 20 recessive 
NB, affects PRs 
and ONL 
2-5 y  109 
SLC4A3 
Golden 
Retriever 
37 recessive 
NB indicates 
rod disease 
variable  61 
C2orf71 
Gordon, Irish 
Setter 
17 recessive NB 10 y ✓ 
118, 
120-
123 
CNGB1 
Papillon, 
Phaléne 
2 recessive 
NB, PR loss, 
cone preserved 
late stage, 
thinning of ONL 
5-6 y ✓ 
I, 
84, 
351-
354 
SAG Basenji 25 recessive 
NB, daylight 
vision retained 
 ✓ 
133, 
136-
138 
MERTK 
Swedish 
Vallhund 
17 recessive 
three stages, 
origin from rods 
or RPE 
variable ✓ 
IV, 
332, 
334-
341, 
355, 
357, 
358 
TTC8 
Golden 
Retriever 
8 recessive 
NB indicates 
rod disease 
variable ✓ 
62, 
116, 
117 
FAM161A 
Tibetan 
Spaniel, 
Terrier 
10 recessive 
typical signs of 
PRA 
4-5 y ✓ 
124, 
126, 
129-
131 
*(PR, photoreceptor, NB, night blindness) 
 
  
1.7.4 X-linked PRAs 
 
An X-linked, late-onset PRA (XLPRA1) has been described in the Siberian 
Husky and Samoyed breeds (Table 3) with a deletion in the retinitis 
pigmentosa GTPase regulator (RPGR) gene68. The affected males have 
progressive loss of rods with a secondary loss of cone cells. The age of 
onset is at young adulthood. Female carriers have focal areas of rod 
degeneration due to random X-chromosome inactivation68. 
Another X-linked PRA, but with early-onset, termed XLPRA2 has been 
diagnosed in mongrel dogs (Table 3)67. XLPRA2 is caused by a different 
deletion in the RPGR gene, which severely affects the early stages of the 
photoreceptor development67. XLPRA2 is very severe and manifests 
during the retinal development. The first clinical signs are detected by 5-6 
weeks and even in carriers the retina fails to develop normally67.  
RPGR is highly expressed in the connecting cilium and in the outer 
segment of photoreceptors149,150. It interacts with intraflagellar transport 
proteins and is hypothesized to function in the cellular trafficking in the 
connecting cilium151. 
In humans, one of the most severe forms of RP is caused by mutations 
in RPGR152-156. The earliest clinical signs in males include night blindness 
with onset at the first decade of life. The disease progresses to a reduction 
in the visual fields and acuity and to blindness by 40 years of age157. 
Similarly to dogs, human female carrier patients exhibit a range of 
phenotypes that can vary from asymptomatic to a severe retinal 
disease158.   
An RPGR-independent X-linked PRA, XLPRA3, has been described in 
Border Collies (Table 3)69. The initial clinical signs are detected around 2-3 
years of age as a loss of peripheral vision, night blindness, pigmentary 
changes and attenuated retinal vessels. The degenerative areas are 
initially focal but evolve towards a generalized degeneration. The mode of 
inheritance was confirmed as X-linked though the causative gene has not 
been found69. 
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Table 3. X-linked PRA affect the males more severly than carrier females. 
Gene Breed CFA Mode of inheritance Phenotype 
Age of 
diagnosis 
Mutation 
found in 
humans  
Ref 
RPGR 
Siberian 
Husky, 
Samoyed 
X recessive 
loss of rods and 
cones (males), focal 
rod regeneration 
(females) 
young 
adulthood ✓ 
68, 
152-
156 
 
RPGR Mongrel X recessive 
early developmental 
stages of the PR 
development 
5-6 weeks ✓ 
67,  
152-
156 
 
- Border Collie X recessive 
loss of peripheral 
vision, NB, 
pigmentary 
changes, evolve to 
generalized 
degeneration 
2-3 y  69 
1.7.5 Cone-rod degenerations 
 
In addition to the typical rod degenerations primary cone-rod 
degenerations (CRD) have been diagnosed in dogs (Table 4). In CRD, 
cone cells degenerate first, followed by rod cells21. As cone cells function 
in bright light, the primary clinical signs involve day blindness21.  
One type of cone-rod degeneration (crd3) is diagnosed in the Glen of 
Imaal Terrier159,160. The affected dogs show complete loss of retinal layers 
and a lack of rhodopsin signal159,160. Photoreceptor cells are shortened 
and disorganized and the ONL is thinner159,160. The disease is diagnosed 
at about three years of age and progresses to an end-stage disease in a 
few years159,160. 
A deletion that removes two exons in the ADAM metallopeptidase 
domain 9 (ADAM9) gene has been identified as a cause of crd3159,160. 
ADAM9 belongs to a group of metalloproteases with multiple functional 
domains such as an N-terminal pro-domain, a metalloprotease domain, a 
disintegrin motif and a cysteine-rich region, an epidermal-growth factor 
(EGF) repeat, a trans-membrane domain, and a cytoplasmic tail with 
potential SH3 ligand domains161. The gene functions in cone cells and in 
the regions of high photoreceptor density162.         
Adam9−/− mice show a progressive degeneration of rods and cones162. 
Their retinas show an abnormal gap between the distal tips of the 
photoreceptor outer segment and the RPE apical membrane162. In 
humans, ADAM9 mutations have been associated with CRD, termed 
CORD9, with a childhood-onset loss of central and peripheral vision162,163. 
  
Another canine CRD model has been described in the Standard Wire-
Haired Dachshund with early-onset CRD164,165. The age of onset varies 
from 10 months to 3 years of age with a late stage disease at 6 years. 
Clinical characteristics include cellophane-like increase in the tapetal 
sheen and pigment migration in the non-tapetal fundus164,165. The ERG 
indicates reduced cone-derived responses already at 5 weeks of age, 
while the rod-derived responses are less affected164,165.   
The causative mutation has been found in the nephronophthisis 4 
(NPHP4) gene166,167. The gene is commonly associated with 
nephronophthisis, a kidney disease168 and nephronophthisis with retinitis 
pigmentosa, Senior- Løken syndrome168. However, NPHP4-deficient mice 
also develop severe photoreceptor degeneration and reduced rod and 
cone ERG responses by 9 weeks of age169. NPHP4 has been reported to 
interact with nephronophthisis 1 (NPHP1), RP GTPase regulator 
interacting protein 1 (RPGRIP1), RP GTPase regulator interacting protein 
1 like (RPGRIP1L) and retinitis pigmentosa GTPase regulator 
(RPGR)150,168,170,171. 
A mutation in retinitis pigmentosa GTPase regulator-interacting protein 
(RPGRIP1) gene, which interacts with NPHP4, has been found in the 
Miniature Longhaired Dachshund172. The affected dogs are diagnosed with 
abnormal ERG at 6 weeks and blindness by the age of 2 years173. The 
disease primarily affects cone cells173. The disease is termed as 
CORD1174. A fully segregating 44-bp insertion in the 3’UTR of the 
RPGRIP1 gene was originally found in a research colony172, however the 
mutation was also present in a normal pet population without 
ophthalmoscopical findings175. A further study of the phenotype led to the 
identification of another locus co-segregating with the RPGRIP1 
mutation176. This indicates that the disease may be digenic and the 
RPGRIP1 mutation alone does not cause the disease phenotype176. 
RPGRIP1 is expressed in amacrine neurons, photoreceptors and in 
many other eye tissues149. Studies in knockout mice indicate that 
RPGRIP1 is required for the morphogenesis of the outer segment (OS) 
discs, particularly in rods177. RPGRIP1 belongs to the cilia protein network 
and is part of various protein complexes in the retina, including RPGR149, 
NPHP4170 and RanB178. In humans mutations in RPGRIP1 causes Leber 
Congenital Amaneurosis179 and recessive retinal dystrophy180.  
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Table 4. Genetically distinct cone degenerations are diagnosed in several breeds. 
Gene Breed CFA Mode of 
inheritance Phenotype* 
Age of 
diagnosis 
Mutation 
found in 
humans 
Ref 
RPGRIP1 
Miniature 
Longhaired 
Dachshund 
15 recessive 
abnormal ERG, 
blindness, cones 
primarily 
degenerated 
6 weeks-
2y 
✓ 
172, 
179, 
180 
NPHP4 
Standard 
Wirehaired 
Dachshund 
5 recessive 
cellophane-like 
increase in tapetal 
sheen, pigment 
migration in the 
non-tapetal 
fundus, reduced 
cone responses, 
rods less affected 
10 mo-3y ✓ 
166, 
168 
ADAM9 
Glen of 
Imaal 
Terrier 
16 recessive 
complete loss of 
retinal layers, lack 
of rhodopsin 
signal, PR 
shortened, 
disorganized, 
thinner ONL 
3y ✓ 
159, 
162, 
163 
 
*(PR, photoreceptor) 
1.7.6 Other retinal degenerations 
 
PRAs and cone-rod dystrophies are progressive and eventually lead to 
complete blindness. However, not all PRAs are progressive (Table 5). A 
retinal dystrophy has been described in the Briard dog, including 
congenital night blindness and partial day blindness observed already in 5-
6 week-old puppies, concurrently with a normal fundus appearance181. 
There is little change in fundus appearance until affected dogs are 3-4 
years old182, when suttle abnormalities can be detected such as whitish 
multifocal spots mainly in the tapetal area. ERGs indicate defects in the 
phototransduction process, most typically with non-recordable ERG rod 
responses and severely reduced cone responses183. Photoreceptors 
appear mainly normal histologically early in the disease process, while 
there is an accumulation of lipoidal material in the RPE183. The disease is 
often called the Briard retinal dystropy but lately the designation canine 
Leber congenital amaurosis has been used for the disorder. 
A mutation in the retinal pigment epithelium 65 (RPE65) gene has been 
indicated as a cause184. RPE65 is vital for the visual cycle and important 
  
for the regeneration of the light sensitive chromophore 11-cis-retinal185,186. 
It has also been shown that in RPE65 deficient dogs, the rod second order 
neuron sprouting is increased in the inferior periphery187. RPE65 is 
expressed in RPE cells188,189, and cone cells190. The S cone opsin 
expression is not uniformly reduced as RPE seems to preserve S-cone 
opsin but not L/M-cone opsin expression187. 
RPE65 causes type 2 Leber congenital amaurosis (LCA) in human 
(OMIM 204100)191 or an early-onset severe retinal dystrophy192,193. Also 
the existing mice models, both induced and spontaneous, exhibit 
progressive retinal degeneration similar to the dog and human194-196. 
A stationary retinal disease, termed canine multifocal retinopathy (cmr), 
is caused by mutations in the bestrophin (BEST1) gene. CMR has been 
described in both English and Bull Mastiffs, and Great Pyrenees (cmr1), 
Coton de Tulear (cmr2) and Lapponian Herders (cmr3)197-199. Breed-
specific alterations in the mutation positions, including a nonsense 
transition (c.C73T/p.R25X) in cmr1, a missense change 
(c.G482A/p.G161D) in cmr2 and a frameshift mutation 
(c.C1388del/p.P463Fs) resulting in a truncated peptide in cmr3, have been 
reported. The affected dogs have multifocal areas of retinal elevation with 
an accumulation of subretinal fluid198,199. The disease may be stationary 
for years, but older dogs may also develop a multifocal outer retinal 
atrophy198. 
The bestrophin protein is located in the basolateral plasma membrane 
of the RPE and it functions as a Ca2+-dependent anion channel200. It 
participates in the epithelial transport across the RPE201,202. 
In humans, over 100 BEST1 mutations have been associated with 
several phenotypes, including bestrophinopathies, a best vitelliform 
macular dystrophy (BVMD), a juvenile-onset macular degeneration, an 
adult-onset foveomacular vitelliform dystrophy, an autosomal dominant 
vitreoretinochoroidopathy, and an autosomal dominant retinitis 
pigmentosa203,204. 
Another example of a stationary canine retinopathy, cone 
degeneration, has been identified in the Alaskan Malamute205. The 
affected dogs develop day blindness and photophobia already at 8-12 
weeks after the postnatal retinal development period due to degeneration 
of cone cells206. The rod cells develop and function normally and the 
affected dogs retain normal night vision206.   
The cone degeneration in Alaskan Malamutes and in the Miniature 
Australian Shepherd is caused by a large genomic deletion (0.4 Mb), 
including all exons of the cyclic nucleotide gated channel beta 3 (CNGB3) 
gene and large parts of the copine III (CPNE3) and cyclic nucleotide 
binding domain containing 1 (CNBD1) genes207,208. The deletion carriers 
have been found also in the Siberian Husky, and in the Alaskan Sled Dog 
breeds208. In addition, a missense mutation in the CNGB3 gene was found 
in a day-blind German Shorthaired Pointer207.  
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CNGB3 encodes the β-subunit of the cyclic nucleotide-gated (CNG) 
channel that represents the light-activated channels located in the cone 
photoreceptors209. The outer segments of the CNG channels consist of α- 
and β-subunits210. α-Subunits can form functional channels by themselves, 
as the β-subunits cannot211. The β-subunits modulate channel properties 
when co-expressed with α-subunits, forming a native CNG channel211. 
Both subunits are essential for normal CNG channel function in the cone 
outer segment plasma membrane and are required for generation of light-
evoked electrical photoresponses in the cones211. Mutations in the CNGB3 
gene lead to abnormal cone function and loss of cone cells as the CNG 
channel in the cone cells is not properly formed212. However, genetic 
heterogeneity has been described in day blind Alaskan Malamutes, as not 
all clinically confirmed cases have the CNGB3 deletion and a yet unknown 
mutation causes the disease in these dogs213.  
In humans, mutations in CNGB3 cause achromatopsia, which is an 
autosomal recessive disease characterized by a loss of cone 
photoreceptors and day-blindness, total colorblindness, and decreased 
central visual acuity214. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5. Examples of other types of retinal degenerations and associated genes and breeds. 
Gene Breed CFA Mode of 
inheritance Phenotype 
Age of 
diagnosis 
Mutation 
found in 
humans  
Ref 
RPE65 Briard 6 recessive 
defect in the 
phototransduction, 
accumulation of 
lipoidal material in 
RPE 
5-6 weeks ✓ 
181, 
192, 
193 
CNGB3 
Alaskan 
Malamute, 
and Sled 
Dog, 
Miniature 
Australian 
Shepherd, 
Siberian 
Husky, 
Shorthaired 
Pointer 
29 recessive 
day blindness and 
photophobia after 
the postnatal 
development, cone 
degeneration, 
normal vision in dim 
light 
8-12 
weeks 
✓ 
207, 
208, 
214 
 
 
BEST1 
English, 
Bull Mastiff, 
Great 
Pyreness, 
Coton de 
Tulear, 
Lapponian 
Herder 
18 recessive 
multifocal areas of 
retinal elevation 
with accumulation 
of subretinal fluid 
variable ✓ 
198, 
203, 
204 
1.8 Glaucoma 
Together with retinal degeneration and cataract, glaucoma is one of the 
most common causes of irreversible blindness215,216. Glaucoma describes 
a heterogeneous group of ocular disorders that are characterized by a 
progressive degeneration of the optic nerve head, optic disk changes, 
focal or generalized thinning of the neuroretinal rim, leading to 
neurodegenereation of the retinal ganglion cells (RGC) and a progressive 
defect in the visual fields (Fig. 3)29. Elevated intraocular pressure (IOP), 
which results from an obstruction of the normal flow of aqueous humor 
through the anterior chamber and the trabecular meshwork, is considered 
a strong risk factor29,217. In humans, glaucoma is a chronic and slowly 
progressive disease that may severely damage the optic nerve and the 
retina before any symptoms are recognized29. 
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Glaucoma can be a primary or secondary disease. It is broadly 
classified into three groups: primary open-angle (POAG), primary closed 
angle (PACG), and primary congenital glaucoma (PCG)218, in all of which, 
the IOP may or may not be elevated29. Genetics of human glaucoma have 
been extensively studied and multiple loci have been mapped for all 
types219-222. However, only few genes have been associated mainly with 
famial glaucoma219,221,222. This indicates that glaucoma is a complex 
disease with both genetics and environment contributing to the disease 
development.  
Similarly to humans, many dog breeds are affected with 
glaucoma219,221,222. Canine glaucoma can be a primary, hereditary 
condition or secondary to some other primary disease such as uveitis or 
lens luxation223. Both primary open and closed angle glaucomas have 
been described in several dog breeds21. Clinical features resemble largely 
human glaucoma including the loss and death of the RGCs, optic nerve 
axonal loss and concurrent optic nerve head cup enlargement with 
incremental reduction in visual fields and blindness with or without IOP 
elevation224. The disease affected both eyes equally, even though the 
disease progression differs between the eyes with the onset varying by 
months or even years224. 
Despite the existence of both POAG and PACG in many breeds the 
genetic etiology of glaucoma is almost completely unknown in dogs (Table 
6). It is hypothesized that both types of glaucoma are inherited but the 
mode of inheritance remains unknown. In Siberian Huskies and in Welsh 
Springer Spaniels, a recessive and a dominant model of inheritance, 
respectively, have been suggested225,226. During this study, a mutation in 
ADAMTS10 was described in Beagles with POAG227 and two 
polymorphisms in SRBD1 were suggested in Shiba Inus and Shih Tzus 
with PACG228. Furthermore, two loci have been suggested for PACG in the 
Basset Hound229, although further studies are required to confirm these 
preliminary associations. 
1.8.1 Primary open angle glaucoma (POAG)  
 
POAG is the most common form of human glaucoma220. It is characterized 
by changes in the ONH and defects in the visual field, with a normal open 
anterior chamber and progressive death of RGC230. The IOP is frequently 
increased, but may also be within the normal range230. 
In humans, the genetic basis of POAG has not been completely 
established due to its heterogeneous etiology218,219,231. Myocilin 
(MYOC)232, neurotrohin 4 (NTF4)233, optineurin (OPTN)234 and WD repeat 
domain 36 (WDR36)235 and at least 20 genetic loci of which 14 are named 
(GLC1A-N) have been suggested for human POAG236,237. Furhermore, 
putative associations have been found for loci including genes ICA1, 
  
RAB9BP1, SLC2A14/SLC2A3, LOXL1, CAV1/CAV2, TCMO1, and 
CDK2BAS238-242. 
Canine POAG has been studied in a research colony of Beagles243-245. 
In canine POAG, the ICA and ciliary cleft are initially open and normal. The 
pectinate ligament is usually normal but may also be slightly dysplastic245. 
As the disease progresses IOP gradually increases, resulting in the ICA 
and ciliary cleft structure closure. The cupping of the optic nerve head 
(ONH) and disappearance of the retinal vessel follow the disease 
progression246. 
In the colony Beagles, POAG is an autosomal recessive disease and a 
mutation in the ADAM metallopeptidase with thrombospondin type 1 motif, 
10 (ADAMTS10) gene has been identified227. ADAMTS10 interacts with 
fibrillin-1 and localizes to fibrillin-1 microfibril bundles247. Microfibrils 
maintain the lens in its position via lens ligaments, which are primarily 
comprised of fibrillin-1248. Fibrillin-1 is also expressed in the outflow 
pathway of the aqueous humor and a defect in the fibrillin-1 may lead to 
impaired aqueous humor flow249-251. Kuchtey et al. demonstrated clinically 
that the affected Beagles have weakened posterior scleral biochemical 
properties and significant alterations in collagen solubility before ONH 
damage252. Their microfibril theory suggests that glaucoma could be 
caused by abnormal microfibril rearrangement252. The ADAMTS10 
mutation was further tested in other breeds and pet Beagles, 
demonstrating that the mutation is limited to the Beagle colony253.   
1.8.2 Primary glaucoma in the Norwegian Elkhound  
 
Norwegian Elkhounds (NE) is a spitz type breed, originating from Norway 
with grey or black fur. It is a common breed in Finland used for elk hunting 
(Fig. 8). The breed is affected with POAG254,255. The disease in NEs is 
commonly diagnosed in middle-aged or elderly dogs, when it starts to 
affect the dog´s hunting capabilities254. However, it is probable that the 
actual disease onset is earlier254. The affected dogs are often brought to a 
veterinarian only when the disease has already developed into a late stage 
disease with a significantly elevated IOP. Early clinical signs in NEs 
include a slightly elevated IOP with a normal opening of the ciliary cleft254. 
The peripheral vision is commonly affected and as the disease 
progresses, the vision is further impaired due to the cupping and atrophy 
of the optic nerve head254. At the later stages of the disease, the narrowing 
or collapse of the ciliary cleft contributes to the elevation of IOP. This may 
lead to secondary subluxation of the lenses in some cases. The retina is 
normal until the late stages of the disease. Other clinical signs may include 
Haab´s striae, cataract, and buphthalmos254. The genetic cause of the 
disease was unknown prior to this study.  
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Figure 8. The Norwegian Elkhound is a spitz type breed, which is affected by primary 
glaucoma. It is common in Finland used to hunt elk. 
1.8.3 Primary closed angle glaucoma (PACG) 
 
PACG in humans is characterized by the shallow anterior chamber, 
increased thickness of the lens, complete or partial chamber angle 
closure, hyperopic refractive error, and short axial length256. Elevated IOP 
is caused by a shallow anterior chamber and the obstruction of the iris-
trabecular meshwork in the iridocorneal angle of the eye, which causes 
blockage of the aqueous humor outflow257,258. 
Recently three loci were associated with PACG, with separate markers 
showing significant association after replication on human chromosomes 
1, 8 and 11, near genes pleckstrin homology domain containing, family A 
member 7 (PLEKHA7), collagen, type XI, alpha 1 (COL11A1), protein-L-
isoaspartate (D-aspartate) O-methyltransferase domain containing 1 
(PCMTD1) and suppression of tumorigenicity 18, zinc finger (ST18), 
respectively257. However, no causative variants have been identified. 
Association studies also suggest the involvement of several single 
nucleotide polymorphisms (SNPs) of the matrix metalloproteinase-9 
(MMP-9) gene259-261. PACG has also been associated with membrane type 
frizzled related protein (MFRP), methylenetetrahydrofolate reductase 
(MTHFR) and the retinal homeobox gene (CHX10)260,262-264. These genes 
are involved in the regulation of axial length and structural remodeling of 
connective tissue. However, this association has not been replicated and 
the biological significance of the gene in the development of PACG is still 
unknown260,262-264. 
Canine PACG is a result of gradually narrowing ICA due to congenital 
malformation of the ICA structure, resulting in a complete closure of the 
ICA angle265. The pectinate ligaments are severely dysplastic, with sheets 
  
of tissue with or without flow holes or broad ligament strands265. A 
significant and progressive defect in RGC function is diagnosed which 
progresses to the retinal photoreceptor cells in the outer retina266,267. The 
loss of RGC correlates with the abrupt and severe elevation of IOP, which 
is commonly associated with PACG224. The abrupt elevation of IOP may 
be caused by the closure of the ICA and blockage of the aqueous humor 
flow224. 
It is hypothesized that female dogs have approximately twice the risk of 
males for developing PACG, due to gender differences in the morphology 
of the ICA268,269. Another suggested factor is age. PACG is usually 
diagnosed in elderly dogs after 6 years of age but the initial onset may be 
earlier as the symptoms become observable only at the later stage of the 
disease when the ICA has narrowed and IOP is significantly elevated224. 
The earlier primary symptoms may go unnoticed if a detailed examination 
is not routinely performed to evaluate the ICA, ciliary cleft and pectinate 
ligament structures224. 
Some dog breeds are more prone to PACG development, including 
American Cocker Spaniel270, Basset Hound271, Boston Terrier59, Bouvier 
des Flandres38, Chow Chow272, English Cocker Spaniel273,274, Flat Coated 
Retriever275, Golden Retriever with iridociliary cysts276, Great Dane277, Toy 
and Miniature Poodles59, Samoyed278, Siberian Husky59, Shih Tzu279 and 
Welsh Springer Spaniel225.  
In dogs, however, little is known about the genetic background of 
PACG. Polymorphisms in the S1 RNA binding domain 1 (SRBD1) gene 
have been associated with PACG in Shiba Inus and Shih Tzus but no 
functional variant has been found yet228. In Basset Hounds, two loci were 
suggested on canine chromosome 14, containing the collagen, type I, 
alpha 2 (COL1A2) and paternally expressed 10 (PEG10) genes and on 
chromosome 24 with a candidate gene RAB22A, member RAS oncogene 
family (RAB22A)229. However the p-values in the associated region did not 
reach the genome wide significance, and require further studies in larger 
study cohorts.  
1.8.4 Primary congenital glaucoma (PCG) 
 
PCG is the most common form of childhood glaucoma and is 
characterized by abnormalities in the anterior chamber angle, elevated 
IOP, corneal oedema, buphthalmos, corneal enlargement, photophobia, 
lacrimation, blepharospasm, corneal opacity, and optic atrophy in the late 
stage disease280,281. Ocular abnormalities in PCG cause obstructed 
aqueous humor outflow. The onset of PCG usually occurs within the first 
few years of life. The disease is often transmitted in an autosomal-
recessive pattern and occurs up to 10 times more frequently in certain 
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ethnic and religious groups where consanguineous relationships are 
common282. 
Three loci (GLC3A-3C)236,237,283 and two genes cytochrome P450 
1B1 (CYP1B1)284 and latent transforming growth factor beta binding 
protein 2 (LTBP2)285 have been suggested to associate with PCG in 
humans. In dogs a congenital origin of PACG or POAG cannot be ruled 
out as the initial disease onset may be congenital, even though clinical 
abnormalities are only detected in older dogs. 
1.8.5 Pectinate ligament dysplasia (PLD) 
 
Pectinate ligament dysplasia (PLD) refers to abnormal pectinate ligament 
structures and it has been diagnosed in many dog breeds (Table 6). PLD 
is used to describe congenital ocular abnormalities in the iridocorneal 
angle (ICA)275. In PLD the abnormalities in the pectinate ligaments consist 
of mesodermal sheet with or without flow holes extending from the base of 
the iris to the peripheral cornea38. The mesodermal sheet may be formed 
of broader PLs or a solid sheet of tissue instead of normal thin strands, 
which causes the narrowing of the ICA (Fig. 9)38. The ICA is thought to be 
abnormal if more than 25 % of the ICA circumference is affected278.  If 
more than 75% of the ICA is affected, PLD is considered severe278. In 
glaucomatous eyes, PLD is usually severe or the whole ICA is collapsed 
(Fig. 9). Gender or age probably does not affect the PLD 
development225,226, 270,278, 286.  
In addition to PLD abnormalities, the narrowing of the relative width of 
the opening of the ciliary cleft (RWOCC) has been associated with 
glaucoma274,278. Bjerkas et al. have showed that in the English Springer 
Spaniel both the PLD and the narrowing of the RWOCC may contribute to 
the development of glaucoma that cannot be visualized in conventional 
gonioscopy274.   
 
  
 
Figure 9. A) The pectinate ligament (PL) form the internal boundary of the ICA, between iris 
and the cornea B) A schematic structure of the pectinate ligament through 
goniolens. C) In normal canine eye ligament structures are presented as a pillar of 
tissue of thin to stout strands of tissue and the aqueous humor flow between the 
ligament strands (arrows). D) In PLD the ligament structure is abnormal with 
broaded PLs (white arrows) and a solid sheet of tissue with flow holes (black 
arrows) E) In severe PLD, the PLs form a solid sheet of tissue (white arrows) with 
occasional flow holes (black arrows) blocking the aqueous humor flow. (pictures 
modified from Holger Funk: www.shiba-dog.de/shiba-klub/glaukom-en.htm and 
www.rhegedspringerspaniels.com/welshie-health.asp, PLD photos in courtesy of 
DVM Sanna Elfving). 
PLD and abnormal ICA has been described in several breeds including 
American Cocker Spaniel270, Basset Hound271, Bouvier des Flandres 
dogs38, English Springer Spaniel274, Flat Coated Retriever275, Great 
Dane277, Samoyed278, Siberian Husky226, Shiba Inu287 and Welsh Springer 
Spaniel225. In many breeds PLD is considered to be hereditary, although 
the mode of inheritance remains unknown (Table 6) 286.  
Dogs with severe PLD have a significantly increased risk of developing 
glaucoma. However, other factors have an effect on the glaucoma 
development as not all dogs with severe PLD develop the disease38,275,286. 
Furthermore, abnormalities in the ICA may be just a clinical marker for a 
triggering disease process originating deeper in the ICA275. A more 
detailed examination would allow a better evaluation of the ciliary cleft and 
iridocorneal angle than the commonly used gonioscopy288. 
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Table 6. PLD and glaucoma have been reported in several breeds. However only four loci 
and one causative gene have been implicated in dogs. 
 
Gene Breed CFA 
Mode of 
Inheritance 
Phenotype 
Mutation 
found in 
humans  
Ref 
ADAMTS10 
Beagle, 
Norwegian 
Elkhound 
20 recessive POAG ✓ 
227, 
V, 
379, 
380 
 
American Cocker 
Spaniel 
  
PACG, 
PLD 
 270 
COL1A2, 
PEG10/RAB22A 
Basset Hound 14/24  PACG  
271, 
229 
 Boston Terrier   PACG  59 
 
Bouvier des 
Flandres 
  
PACG, 
PLD 
 38 
 Chow Chow   PACG  272 
 
Dandie Dinmont 
Terrier 
8 recessive? 
PACG, 
PLD 
 III 
 
English Cockers 
Spaniel 
  PACG  273 
 
English Springer 
Spaniel 
  PLD  274 
 
Flat Coated 
Retriever 
  
PACG 
, PLD 
 275 
 Golden Retriever   
PACG and 
iridociliary 
cysts 
 276 
 Great Dane   
PACG, 
PLD 
 277 
 
Toy, Miniature 
Poodle 
  PACG  59 
 Samoyed   
PACG, 
PLD 
 278 
 Siberian Husky  recessive? 
PACG, 
PLD 
 59 
 Shih Tzu 10 recessive PACG  
228, 
279  
 Shiba Inu 10 recessive 
PACG, 
PLD 
 
228, 
279 
 
Welsh Springer 
Spaniel 
 dominant? 
PACG, 
PLD 
 225 
  
1.9 Dog as an animal model for ocular gene therapy 
Retinal degenerations and glaucomas have been extensively studied in 
dogs and several genes have been found. Most canine genes have been 
the orthologues to those identified in human retinal degenerations and 
glaucoma17,289. 
The genetic and pathological findings in dogs have significantly 
contributed to the understanding of the disease mechanism in humans290-
293. Novel retinal degeneration genes found in dogs have subsequently 
been identified in human patients63,80,92. 
The identification of mutations causing retinal degenerations has 
provided important canine models for ocular gene therapies prior to 
translation into human patients294. Disease prevention, stabilization and 
the degenerative process can be efficiently modeled in dogs294. The 
dimensions of the canine eye are similar compared to the human eye, 
despite smaller vitreous volume and the lack of the foveo-macular 
region295. 
Viral vectors, especially recombinant adeno-associated viruses (rAAV) 
have provided the most promising results in canine gene therapy trials290-
293. The part targeted most often is the retina. Being anatomically well-
defined and readily accessible, the retina offers several advantages. The 
most typically targeted part of the retina is the RPE or photoreceptor 
cells294. In addition to rAAV mediated therapy, combinatorial treatments 
including delivery of agents to prevent the loss of retinal cells, such as 
neuroprotective, prosurvival, or anti-apoptotic factors or antioxidants, 
sequentially or simultaneously with gene augmentation therapy are under 
development294. 
The first successful gene therapy trial in dogs paved the way for a gene 
therapy for human LCA (RPE65). In RPE65 trials, the proof-of-principle 
studies in young RPE65-deficient dogs showed that rAAV vectors 
expressing either human or canine RPE65 dramatically improved 
photoreceptor function290-293. The LCA gene therapy has been the first to 
be implemented in human patients296-300 and has been shown to improve 
the patient´s visual function, especially in children301. However, despite 
functional recovery, the disease progression continues both in humans 
and in dogs, implying that the gene replacement therapy alone may not be 
sufficient and combinatorial treatments may be required302.  
Other canine gene therapy trials are currently being developed for 
canine achromatopsia (CNGB3) and X-linked PRA (RPGR). In the former, 
a successful canine gene therapy trial has been reported, in which the 
cone function and associated photopic vision were restored303. rAAV 
vectors with different human red cone opsin promoters were used and the 
results suggested that the treatment was mutation independent, but 
promoter and age dependent303. Furthermore, the CNGB3-achromatopsia 
study showed that a combined staged therapy of ciliary neurotrophic factor 
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(CNTF) and rAAV vector successfully restores cone function at older age 
(14–42 months) when gene augmentation therapy alone cannot304. 
Currently, no human gene therapy has been developed for achromatopsia, 
but the canine gene therapy trial provides a successful path for translation 
to human patients.  
Similar trials have been developed also for the canine XLPRA caused 
by the RPGR gene. Beltran et al. showed that gene augmentation in both 
rods and cones with the full-length human RPGR driven by two separate 
promoters, prevented photoreceptor degeneration and preserved the 
retinal structure and function 305. Although the canine gene therapy for 
XLPRA has been successful in a small number of treated animals305, 
human studies could be more complicated due to disease modifiers 
affecting the large spectrum of RPGR-XLPRAs phenotypes seen in 
patients306. 
  
2 AIMS OF THE STUDY 
The overall aim of this study was to identify the genetic causes of two 
degenerative ocular disorders, retinal degeneration and glaucoma, in five 
different dog breeds. An increased prevalence of the diseases has been 
reported in certain breeds, suggesting a genetic predisposition. A 
collaborative effort combining basic research and clinical studies was 
embarked on to establish clinically relevant study cohorts in each breed to 
identify the genetic background of the disorders. 
 
The specific aims of this study were: 
 
I. To identify the causative mutation for PRA in Papillon and 
Phaléne breeds 
 
II. To describe the clinical phenotype of primary glaucoma in 
Dandie Dinmont Terriers and map the disease gene 
 
III. To clinically characterize the retinopathy phenotype and to find 
the causative gene in Swedish Vallhunds 
 
IV. To identify the mutation causing primary glaucoma in Norwegian 
Elkhounds 
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3 MATERIAL AND METHODS 
3.1 Study cohorts and pedigrees 
DNA samples were collected to the canine DNA repository established by 
Professor Hannes Lohi at the University of Helsinki and Folkhälsan 
Research Center, Helsinki, Finland. The DNA bank currently contains over 
50,000 DNA samples from 327 different dog breeds and serves as an 
excellent resource for the genetic research, also in canine vision disorders. 
Donors were recruited by advertising the research in the website 
(www.koirangeenit.fi), contacting the relevant breed clubs and through 
social media, such as Facebook. An extensive phenotype and genotype 
database has been established to maintain information about the dogs and 
owners. All samples were collected from privately owned pet dogs with the 
owners consent under the permission of the Animal Ethical Committee of 
County Administrative Board of Southern Finland 
(ESAVI/6054/04.10.03/2012) and University of Pennsylvania IACUC 
protocols # 802604 and 803429 (Study III, IV and V). 
Large pedigrees were constructed around the affected dogs with a 
GenoPro genealogy software (www.genopro.com) using the genealogical 
data available in public canine registries such as the database maintained 
by the Finnish Kennel Club (jalostus.kennelliitto.fi) and Hunddata 
maintained by the Swedish Kennel Club (hundar.skk.se/hunddata/), or 
information provided by the owners. All pedigrees can be found in each 
separate study. EDTA-blood or buccal samples were collected by a 
veterinarian or trained specialist for different studies as follows: 
 
Study I: Samples from 59 Papillons and from 116 Phalènes were 
collected, including 4 Papillons and 2 Phalènes with clinical signs 
consistent with PRA and 14 control dogs that were confirmed healthy in an 
eye examination at the age of over 7 years. 
 
Study II: Samples were collected from 33 DDTs diagnosed with glaucoma 
and 159 control dogs. In addition, 35 samples were collected from DDTs 
affected with PLD. Control dogs were over 7 years old and had been 
confirmed to have healthy eyes although the presence of mild PLD (grade 
1) was tolerated. The fine mapping study included dogs older than 5 years. 
In addition, samples were collected from Siberian Huskies with uni- or 
bilateral glaucoma and increased IOP, Flat Coated Retrievers, and Welsh 
Terriers presenting mild to severe PLD with a narrowed or closed ICA. 
 
Studies III and IV: Samples were collected from 93 retinopathy-affected 
and 76 unaffected dogs, and from 436 SVs altogether. Controls dogs were 
  
over the age of six years and were confirmed to be free of retinal disease. 
In study III, ocular histopathologic samples were obtained from 8 SVs, that 
were euthanized for unrelated reasons, and the eyes donated by the 
owners. Paraffin sections of normal and affected eyes originating from 
other canine breeds were provided as control samples by the Anatomic 
Pathology/Biopsy Service of the University of Pennsylvania School Of 
Veterinary Medicine and the Comparative Ocular Pathology Laboratory of 
Wisconsin (COPLOW). In addition, samples from mixed breed colony dogs 
were obtained from the Retinal Disease Studies Facility at the University of 
Pennsylvania, School of Veterinary Medicine. In study IV retinal samples 
were collected from four retinopathy affected dogs, that were euthanized 
for unrelated causes.  
 
Study V: Samples were collected from 16 glaucoma affected, dogs 9 
controls and 572 population dogs. The control dogs were eye examined at 
the age of at least 8 years old and did not show any clinical signs of 
glaucoma.  
 
In all studies additional DNA and tissue samples from the DNA-bank were 
utilized to study the genes and variants within the breeds and at the 
population level.  
3.2 Genomic DNA and RNA extraction 
Genomic DNA was extracted from EDTA blood or buccal samples, using 
Chemagic Magnetic Separation Module I (MSM I) (Chemagen Biopolymer-
Technologie AG, Baeswieler, Germany) according to the manufacturer’s 
instructions. DNA from buccal swabs (Eurotubo Cytobrush, sterile, 
200mm, Danlab, Helsinki, Finland) was extracted using QIAamp DNA Mini 
Kit (Qiagen). 
Retinal samples from an Australian Cattle Dog (Study I and IV) and 
Swedish Vallhunds (Studies III and IV) were transferred to RNAlater 
stabilization and storage solution (Life Technologies). RNA was extracted 
using RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions.  
DNA and RNA concentrations were measured using Nanodrop ND-
1000 UV/Vis Spectrophotometer (Nanodrop technologies, Wilmington, 
Delaware, USA) and the samples were stored at -20°C (DNA) or -80°C 
(RNA). 
3.3 Clinical and laboratory studies  
Phenotyping was based on detailed clinical studies (II and III) in Dandie 
Dinmont Terrier and Swedish Vallhunds, as no previous published clinical 
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data was available. Other phenotypes (I and V) in the Papillon, Phaléne 
and Norwegian Elkhound were based on ophthalmological reports from 
ECVO panelists. The clinical studies were performed using several 
methods including electroretinography (ERG), fundus photographs, 
gonioscopy, histopathologic examination, immunohistochemical staining, 
indirect ophthalmoscopy, laser scanning confocal microscopy light and 
fluorescent microscopy, neuro-ophthalmic examination, serum vitamin E 
measurements, slit lamp biomicroscopy, and tonometry. Different methods 
were used in each study.  
 
Papillon and Phaléne (Study I): Phenotyping was based on 
ophthalmological reports. All affected dogs were eye examined by ECVO 
panelists at least once. The affected dogs represented typical clinical signs 
of late-onset PRA. 
 
Dandie Dinmont Terrier (Study II): A complete ophthalmic examination 
was performed on 18 Finnish Dandie Dinmont Terriers (3-13 years) 
without glaucoma, including neuro-ophthalmic examination, tonometry, 
indirect ophthalmoscopy, slit lamp biomicroscopy and gonioscopy. A 
detailed description the clinical examination is provided in Study II. 
The anterior width of the ciliary cleft and the total distance from the 
origin of the pectinate ligament to the anterior corneal surface were 
subjectively evaluated. The ratio was used as an estimate of the RWOCC, 
which was graded as open, slightly narrow, narrow or closed.   
The degree of the pectinate ligament dysplasia was categorized on the 
basis of the ECVO (www.ecvo.org) guidelines in both eyes. The ICA was 
judged to be affected by PLD, when it exhibited abnormally broad and 
thickened pectinate ligament fibres or solid sheets of pectinate ligament 
tissue, with or without ”flow holes” over 25% or more of the circumference. 
Dogs with PLD were graded 0-3 on the basis of the percentage of 
dysplasia present (Study II/Table 1). Intraocular pressure was measured 
on undilated eyes from all 18 unaffected dogs and post-dilation from 16 
dogs.  
The association between the PLD and ICA narrowing and age, possible 
PLD or the narrowing of ICA and their association to with gender and the 
association between PLD and glaucoma were evaluated. Detailed 
statistical analysis can be found in Study II. 
  
Swedish Vallhund (Study III): All SVs were examined by indirect 
ophthalmoscope and with slit-lamp biomicroscopy. Fundus photographs 
were taken in selected dogs. All ocular abnormalities were documented. 
ERG was recorded in 15 SVs. Ocular histopathologic examination was 
performed in 8 SVs. The cell morphology and the localization of protein 
expression within the retina were studied. The immunohistochemical 
staining of retinal sections were performed with antibodies listed in Study 
  
III/Table S1. Tissues were evaluated using light and fluorescent 
microscopy and imaged by laser scanning confocal microscopy. Serum 
vitamin-E measurements were performed in 19 dogs, including normal and 
affected SVs as well as mixed breed colony dogs. Detailed measurement 
techniques, histology and the imaging protocols are described in Study III. 
To identify any possible environmental risk factors contributing to the 
development and progression of the disease, a short questionnaire was 
distributed to dog owners and breeders including inquiries about 
husbandry practices and previous occurrence of any systemic or ocular 
disease. Additionally, visual performance was assessed by distributing of a 
short questionnaire among 40 owners of affected SVs in Finland. 
Specifically, the questions concerned the owner’s perception of the onset 
and severity of visual deficits observed in the dogs.  
 
Norwegian Elkhound (Study V): Phenotyping was based on 
ophthalmological reports. All affected dogs were eye examined by ECVO 
panelists at least once. The affected dogs represented symptoms of 
primary glaucoma with significantly elevated IOP, with various degrees of 
optic nerve atrophy and cupping, and a progressive vision loss. Secondary 
clinical signs included lens luxation, corneal stromal edema, Haab´s striae, 
keratitis, vitreal syneresis and retinal degeneration.  
3.4 Genetic analyses 
Several different statistical approaches and genetic methods were used in 
this study. Statistical approaches included genome wide association 
analysis (GWAS), linkage and combined association and linkage analysis. 
Genetic approches included several molecular biology protocols such as 
SNP arrays, iPLEX SEQUENOM MassARRAY with custom SNPs, 
fragment analysis, exome and targeted resequencing, Sanger sequencing 
and RNA studies. Detailed descriptions of the methods and related 
statistical approaches can be found in each separate study. 
 
Genome wide association study (GWAS) (Studies I, II, IV, V): The 
GWAS genotyping was performed using Illumina’s CanineHD BeadChip 
with 173,000 markers (Study I and V) or Illumina Canine SNP20 BeadChip 
arrays with 22,000 markers (Studies II and IV) (San Diego, CA, USA). 
Genotyping was performed in our core facility at the FIMM Technology 
Center (Study I, II and IV) or at Geneseek (Lincoln, NE, USA, Study V).  
 
Fine-mapping (Study II): Fine mapping was performed for 190 DDTs 
including 33 cases and 157 controls, using110 additional custom SNP 
markers (~1 marker/100 kb) between 18 Mb to 29 Mb on CFA8 using 
iPLEX SEQUENOM MassARRAY platform (San Diego, CA, USA).  
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Fragment analysis (Study III): The candidate genes (BEST1, CNGB3, 
NPHP4, PDE6B, PDE6A, PRCD and RPE65) were studied using a 
fragment analysis and a pooling method with flanking microsatellite 
markers. The case (n=11) and control (n=11) DNAs were pooled and 
fragment sizes were compared between the case and control pools. The 
markers, where differences between the pools were found, were amplified 
and analyzed separately.  
 
Sequencing: Three sequencing methods, exome sequencing, targeted 
resequencing and traditional Sanger sequencing were utilized in this study 
to identify the causative variants. This was followed by data analysis and 
filtering according to the suggested mode of inheritance. Sanger 
sequencing was used to genotype individual SNP, variants and coding 
regions of the candidate genes. 
 
Exome sequencing (Study I): Exome sequencing was performed for a 
trio of Phalènes, including an affected proband and healthy parent dogs 
(Study I/Fig. 1). The coding sequences were captured using Agilent’s 
Canine Exome Capture Kit (Agilent, Santa Clara, CA, USA) and paired-
end sequenced with the Illumina HiSeq2000 sequencing machine in our 
core facility at the FIMM Technology Center, according to manufacturer´s 
instructions. 
 
Targeted resequencing (Study IV): The associated region of 6.1 Mb on 
CFA17 was targeted and resequenced from four affected and four healthy 
control SVs. The regions were captured using custom designed probes for 
the build 2.0 of the canine genome reference sequence with the Roche 
Nimblegen solution based capture method. The capture was performed 
according the manufacturer’s instructions and the paired-end sequencing 
was performed using the Illumina HiSeq2000 in our core facility at the 
FIMM Technology Center, according to manufacturer´s instructions. 
 
mRNA studies: The entire CNGB1 mRNA was amplified in a retinal 
sample from an Australian Cattle Dog, free of PRA (Study I). The 
sequence was stored in the NCBI GenBank database (XM_848817.1). 
The MERTK mRNA was sequenced from one unaffected Australian Cattle 
Dog and two retinopathy affected SVs (Study IV). RT-PCR was performed 
for candidate genes MERTK, NPHP1, ANAPC1 and KRCC1 (Study IV) in 
four affected SVs and two unaffected dogs, Australian Cattle Dog and 
Belgium Shepherd. GAPDH housekeeping gene was used as a 
normalization control. More detailed description about the RT-PCR can be 
found from study IV. 
 
  
Sanger sequencing (Studies I, II, IV and V): Sequencing primers were 
designed using Primer3 software 
(biotools.umassmed.edu/bioapps/primer3_www.cgi).  
Reference sequences were obtained from the NCBI database 
(www.ncbi.nlm.nih.gov/). Detailed primers, PCR protocols, and sample 
and variant lists are described in each separate study. The Sanger 
sequencing in each separate study is described in the following chapters.  
 
Study I: The RPGRIP1 gene was studied as a candidate gene by 
sequencing the known insertion mutation172. The SNP on CFA1 
(BICF2P839236) showing the strongest association was amplified in six 
PRA affected and 168 control Papillons and Phalénes. An indel in the 
CNGB1 and a non-synonymous variant in OGFOD1, identified through the 
exome sequencing, were amplified from 6 PRA affected and 150 Papillons 
and Phalènes and one Rough Collie (CNGB1) and from 6 PRA affected 
and 14 control Papillons and Phalènes and one Rough Collie (OGFOD1). 
The CNGB1 variant was further sequenced from 121 dogs from other 
breeds affected with PRA or retinal degeneration, representing 44 breeds 
and 334 healthy control dogs from 10 breeds (Study I/Table S3).  
 
Study II: The glaucoma locus on CFA8 was tested in three other breeds 
affected with glaucoma or PLD by sequencing the three SNPs with the 
strongest association (Study II/Table S3). In addition to candidate loci the 
coding sequence and flanking splice sites of candidate genes CTAGE5, 
FBXO33, LRFN5, PNN and TRAPPC6B were sequenced.  
 
Study IV: A replication study for the SNP (BICF2G630207991) on CFA17 
was performed by genotyping it in additional 34 cases and 26 controls. In 
addition, the variants (n=30) identified on the basis of the targeted 
resequencing were genotyped in a large sample cohort of SVs (Study 
IV/Table 1) and from 8 unaffected dogs from 2 other breeds, Finnish 
Lapphund and Whippet, to study breed specificity.   
 
Study V: The coding regions and splice sites of ADAMTS10 were 
sequenced in four NE cases, four NE controls (unaffected at >8 years), 
and in one unaffected Rough Collie. The identified candidate mutation was 
validated in 596 NEs, including 7 additional cases. In addition, the 
mutation was studied in 71 dogs from 17 other breeds affected with 
POAG, PCAG or PLD and in 115 unaffected dogs from 6 breeds (Study 
V/Table S1).  
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3.5 Statistical analyses 
In GWAS studies a case-control association test was performed using 
PLINK 1.07307. Quality control procedures were included when analyzing 
the data. Only SNPs that met the Hardy-Weinberg expectations of P ≤ 
0.0001, had ≥95% genotyping rate and a minor allele frequency (MAF) of 
5% were included in the analysis. Significance values from these analyses 
were used to generate a whole-genome association plot using the 
statistical package R308. Identity-by-state (IBS) clustering and CMH meta-
analysis (PLINK) were used to adjust for population stratification (Study II 
and V). Genome-wide corrected empirical p-values were determined by 
applying 100,000 (Study I and V) or 50,000 (Study II and IV) permutations 
to the data. In addition the data was analysed using a R-implemented 
GenABEL309 and Gapit310,310 analysis packages. The build 2.0 (Study I and 
II) or 3.1 (Study IV and V) of the canine genome reference sequence was 
used in the studies. 
The fine-mapping data (Study I) was analyzed with PLINK 1.07307 with 
at least 65% genotyping rate and MAF 5 %, resulting in the exclusion of 16 
SNPs out of 110 and 20 individuals out of 190. Association and haplotype 
analysis for 3-SNP and 5-SNP haplotypes were performed using PLINK 
1.07 sliding window option307. 
A linkage analysis (Study I) was performed using the joint family-based 
linkage and association analysis program Pseudomarker311. The family-
based analyses were performed under a recessive inheritance model, and 
included a parametric single-point linkage test, association analysis 
(LD|Linkage) and joint analysis (LD+Linkage). 
Sanger sequence analysis was performed using Variant Reporter 
(Applied Biosystems, Foster City, California, USA) or Sequencher 
softwares (Gene Codes, Ann Arbor, MI, USA) and the fragment analysis 
data (Study III) was analyzed using a Peak ScannerTM Software v1.0 
(Applied Biosystems). 
The effect of the variants on the protein was predicted using 
bioinformatics tools Polyphen2.0312 and SIFT313. The presence of non-
synonymous variants in the exonic enhancer regions in Study V was 
evaluated using ESE-finder314.  
The next generation sequencing data analysis for exome and targeted 
data included quality control, alignment to CanFam2.0 (Study I) or to 
CanFam3.1 (Study IV) reference sequences, variant calling with GATK315 
and Samtools316 softwares and annotation of the variants to NCBI, 
Ensembl and UCSC databases with ANNOVAR317 (Study I) or SnpEff318 
(Study IV) and an in-house R-script. Pindel program was used to identify 
structural variants319. 
The data was then filtered assuming a recessive mode of inheritance 
using in-house R-scripts. In Study IV to identify the case-specific variants, 
the data was filtered against the controls and 16 other dogs from two 
  
breeds, Dandie Dinmont Terrier and Staffordshire Bull Terrier. To study 
the CNVs and repeat elements (SINE, LINE), a heatmap analysis was 
performed by comparing normalized read depth in each position between 
cases and controls to study the possible lack or enrichment of the read 
depth. A more detailed description of the analysis pipeline can be found in 
Studies I and III. 
To compare the vitamin-E levels, a Wilcoxon rank sum test was 
performed to compare the values between groups (Study III).  
The statistical analysis of the clinical data in Study II and the qPCR 
data in study IV were performed using SPSS statistic package320. In study 
II Spearman correlation was used to calculate the association between 
PLD and ICA narrowing and age and PLD or the narrowing of ICA and 
association with gender was evaluated using non-parametric Kruskall-
Wallis test. The association between PLD and glaucoma was determined 
using Chi-square test. In study IV the comparative ΔΔCt-method was used 
to determine relative expression differences. Statistical significance of the 
expression differences was calculated by using the Student's t-test on 
normalized mean cycle threshold (Ct) -values. 
The relative risks were calculated using R-implemented epitools 
package321 in Studies I, III-V, and a Fisher´s exact test was used to 
calculate the association of the candidate variants in a larger sample 
cohort in Studies I, III, and V. 
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4 RESULTS  
4.1 Mutation in the known human RP gene, CNGB1, in 
PRA affected Papillons and Phalenes (Study I) 
A high prevalence of PRA was noted among the breeds. A pedigree was 
drawn around the affected dogs to evaluate the inheritance model for 
study design (Study I/Fig. 1). At the same time an affected dog was gene 
tested as a homozygous for the known RPGRIP1 mutation reported by 
Mellersh et al.172. Because of this, five additional cases and 146 controls 
were screened for the RPGRIP1 mutation, but although a high carrier 
frequency (17.1 %) was found in the breeds, the rest of the affected dogs 
did not carry the mutation, suggesting another genetic cause. This 
promted us to perform a GWAS combined with an exome sequencing to 
map the PRA locus and, identify the mutation in our small study cohort 
with 6 cases and 14 controls. 
The strongest association in GWAS was identified on CFA2 at 61.4 Mb 
(praw=4.7x10-6, pgenome=0.1). Another tentative region was found in CFA1 
(70.3-77.6 Mb) (praw=7.0x10-6, pgenome=0.2). Re-analysing the data by 
adjusting for the strongest SNP on CFA2 (p=0.9) or genotyping the SNP 
with the strongest association on CFA1 (p=6.97x10-5) in a larger sample 
cohort did not improve the original association (Study I/Fig. 2A). The 
association results were confirmed by a joint family-based linkage and 
association analysis using the Pseudomarker program311. The joint 
analysis identified the most highly linked region covering CFA2 61.1-64.9 
Mb, (plinkage=1.0x10-6, passociation=8.7×10-6 and pjoint analysis =1.9×10-7) (Study 
I/Fig. 2B). A homozygous haplotype (1.9 Mb) was shared by cases with 
recessively segregating markers between 61.4-64.5 Mb, including 37 
genes (Study I/Fig. 2C).  
The exome sequencing data identified altogether 129,590 single 
nucleotide variants (SNVs) and 25,905 indels across the trio. More 
information about the exome sequencing results (read depth, on target 
coverage etc.) can be found in Study I/Table S2. After filtering the data for 
the trio according to a recessive mode of inheritance, 204 SNVs and 9 
indels remained. Two coding variants were located in the associated 
region on CFA2: a 1-bp deletion followed by a 6-bp insertion in the cyclic 
nucleotide gated channel beta 1 (CNGB1) gene 
(c.2685delA2687_2688insAGCTAC) (Study I/Fig. 2D) (Fig. 10) and a non-
synonymous mutation in the 2-oxoglutarate and iron-dependent 
oxygenase domain containing 1 (OGFOD1) gene (c.1128G>A). The indel 
variant in CNGB1 causes a frameshift and a premature stop-codon 
p.Tyr889Serfs*5 in an evolutionarily conserved region (Study I/Fig. 3A, B), 
  
while the missense mutation p.M376I in OGFOD1 was predicted to be 
benign. No case-specific variants were found on CFA1.  
Based on the position of the CNGB1 indel and the formation of a 
frameshift, followed by a premature stop codon, it is hypothesized that the 
mRNA is subjected to nonsense mediated decay (NMD). NMD eliminates 
the production of mRNA that contains premature translation termination 
codon in a certain position before the next exon-exon junction and codes 
for nonfunctional polypeptide322,323. However, the NMD hypothesis was not 
tested due to a lack of tissue samples, but we were able to show that 
CNGB1 is expressed in the normal canine retina.  
 
 
Figure 10. An indel mutation in the CNGB1 gene with a 1-bp deletion and a 6-bp insertion in 
the affected dogs. 
To gather further evidence for the CNGB1 mutation, six additional PRA 
affected dogs, four obligatory carriers from the pedigree (Study I/Fig. 1) 
and 145 randomly selected Papillons and Phalènes were genotyped. All 
affected dogs were homozygous and carriers heterozygous for the 
mutation. Four additional homozygous dogs were found among the 145 
dogs. Of these dogs, two were taken to the ECVO panelist and were also 
found to be clinically affected. However, the owners had not noticed any 
abnormalities in the dog´s behavior, indicating that a dog manages well 
even with impaired vision, as previously described145. Two other 
homozygous dogs had been ophthalmoscopically examined at a very 
young age (1-2 years), and it is likely that the clinical signs are not present 
at this age. Based on the genotyping of a larger sample set a 17.2 % 
carrier frequency (25/145) was indicated (pFisher=1.4×10−8). The mutation 
was screened for additional 334 healthy dogs from 10 other breeds without 
PRA and in 121 dogs from 44 other breeds affected with PRA or retinal 
degeneration, but the indel was not present in any of them, indicating that 
the CNGB1 mutation is causal and breed-specific in Papillons and 
Phalènes (Study I/Table S3).  
The CNGB1 gene encodes a rod photoreceptor cyclic guanosine 
monophosphate-gated (cGMP) channel β-subunit, which is part of the 
cyclic nucleotide gated (CNG) channel324-326. The phototransduction 
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cascade is mediated by the CNG cation channel, which is directly gated by 
cGMP327. The gene is expressed in multiple different tissues, including rod 
cells in the retina328,329, making it a highly relevant gene for the studied 
phenotype. 
4.2 Primary closed angle glaucoma in Dandie Dinmont 
Terriers maps to a syntenic region of the human 
chromosome 14 with several glaucoma loci (Study 
II) 
The Dandie Dinmont Terrier (DDT) is a hunting terrier with a very long 
body, short legs, and a distinctive "top-knot" of hair on the head. It was 
named after a character in a novel written by Sir Walter Scott in 1814. All 
the Dandies around today descend from a dog found in a trap on the Duke 
of Buccleuch's estate - in 1839. Today DDTs are rarely used as a working 
terrier, but still make good companion dogs (Fig. 11). Breed clubs in the 
USA, UK and Finland contacted us about the increasing prevalence of the 
disease in the breed, suspecting a genetic contribution. In collaboration 
with the breed clubs, a genetic study was embarked on and DNA samples 
were collected from affected and unaffected DDTs around the world. 
The clinical results revealed that the average age at the glaucoma 
diagnosis was 7.7 years and that several ocular abnormalities concerning 
ICA and PL structures were observed in the majority of the studied 
unaffected dogs. PLD was diagnosed in 72.3 % of the dogs and abnormal 
ICA width was found in 50 % of the dogs (Study II/Table 2). In the dogs 
with normal ICAs, PL was mostly normal with some slight changes in less 
than 50% of the circumference of the PL (<50%). Four of the studied dogs 
had no ocular changes with both PLD and ICA found to be grade 0 (Study 
II/Table 2). Fundi were normal in 14 of the studied dogs. Four dogs had a 
slight arteriole narrowing on the periphery of the retina, which is probably 
due to the age of the dogs (8-13 years). No association between age or 
gender and PLD or ICA narrowing was observed (pPLD=0.45, pICA=0.71, 
pPLD=0.40, pICA=0.77, respectively). PLD was suggested as a risk factor for 
glaucoma development (P=0.05). 
  
 
Figure 11. The Dandie Dinmont Terrier is a terrier with very long body, short legs, and a 
distinctive "top-knot" of hair on the head.  
The GWAS identified a 9.5 Mb associated region on CFA8 (praw=5.8x10-6, 
pgenome= 5.5x10-3), ranging from 20.04 Mb to 29.5 Mb and a further CMH 
meta-analysis performed to correct for the stratification confirmed the 
association (praw=2.21x10-5, pgenome= 0.02) (Study II/Fig. 1A-C). 
Fine-mapping was performed in a replication cohort and identified the 
best association at 22.7 Mb (p=6.3x10-5). When the whole dataset was 
combined, the strongest association was found for the SNP, 
BICF2P1308530 T>C (22.7 Mb). Based on the allele frequencies, the T 
allele was found in 52 % of the cases compared to 14 % in controls 
(p=5.3x10-9, OR=6.6). Homozygosity for the T allele increased the risk 32-
fold (95% C.I. 3.7-280.8, 19% frequency in cases and 0.7% controls). The 
fact that the risk increased with homozygosity suggests a recessive 
inheritance possibly with a reduced penetrance as not all offspring born to 
affected parents are affected. 
A haplotype analysis with a 5-SNP window narrowed the locus to 1.6 
Mb between 22.0 and 23.6 Mb (p=1.6x10-10) (Study II/Fig. 1D). Besides 
this region, three other significant associations at 19.7 Mb (p=2.8x10-6), 
25.57 Mb (p=6.6x10-5) and 26.9 Mb (p=1.0x10-6) were found (Study II/Fig. 
1D).  
The 1.6 Mb locus contained 7 genes of which CTAGE5, FBXO33, 
LRFN5, PNN, and TRAPPC6B were selected for candidate gene 
screening. Sequencing revealed six coding and 12 intronic variants (Study 
II/Table S4). However, none of the variants was case-specific and are 
therefore unlikely to be causative for the disease. The non-causative role 
was further supported by the bioinformatics prediction tools (Study II/Table 
S4). The three most highly associated SNPs were genotyped in four other 
breeds affected with glaucoma or PLD, but no association with either 
phenotype was observed in any of the breeds (Study II/Table S3). 
The CFA8 locus is syntenic to human chromosome 14, which has been 
associated with POAG and PCG, but not PACG (Fig. 12).  
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Figure 12. The canine locus on CFA8 is syntenic to human chr14. Several glaucoma loci for 
POAG and PCG have been mapped to chr14. The canine locus maps to q21.2-
q21.3 (B). In humans 35 genes (A) and dogs (C) 21 genes are located in the 
associated canine locus in DDTs. 
4.3 A unique form of retinopathy in the Swedish 
Vallhund is caused by upregulation of MERTK 
(Studies III and IV) 
The SVs are short coated, small, spitz type herding dog with various coat 
colors and either a tall, stub or bob tail originating in the Viking era (Fig. 13 
A, B). To establish the genetic study, a total of 199 SVs were examined 
during the study and eye examination data from 125 SVs was evaluated 
on the basis of ophthalmological reports. A high (34.9 %) disease 
prevalence was indicated. The individual affected dogs were followed over 
time and three disease stages based on the severity of the clinical signs 
were defined (Study III/Tables 1 and 2). 
Stage 1 was characterized by a diffuse multifocal red or brown 
discoloration of the tapetal fundus, but no visible lesions in the non-tapetal 
fundus or clinical signs of vision loss (Fig. 13 D) were observed compared 
with a normal fundus (Fig. 13 C). A total of 34 dogs were seen with a 
mean age of 4.3 ± 3.7 years, but these initial signs were noted as early as 
1.9 months and as late as 17.8 years of age (Study III/Fig. 2D-F).  
At the Stage 2 the retina showed signs of degeneration, with 
multifocal, geographic thinning, beginning in the periphery and spreading 
throughout the tapetal fundus (Fig. 13E). The majority of dogs did not 
appear to have vision problems initially, even though some owners 
reported mild to moderate signs of night-blindness. A total of 25 dogs were 
found to have the stage 2 of the disease. The mean age at diagnosis was 
6.2 ± 3.1 years, but changes were seen as early as 1.1 and as late as 12.6 
years of age (Study III/Fig. 2G-I).  
Stage 3 was characterized by more diffuse retinal thinning affecting 
most of the tapetal fundus (Fig. 13F). The dogs suffered from loss of night-
vision and severely impaired day-vision. Some dogs were assessed as 
  
completely blind by their owners. These changes were diagnosed in seven 
dogs with a mean age of 12.2 ± 2.6 years, but were also observed as early 
as 9.2 years and as late as 15.4 years (Study III/Fig. 2J-L, Fig. 4B).  
A total of five dogs were followed at stage 1 for a minimum of 0.9-2.3 
years without any signs of progression to subsequent disease stages 
(Study III/Table 2). The precise duration could not be estimated as the pet 
population was distributed across several continents. One notable 
example is a dog that never progressed beyond stage 1 although was 
repeatedly examined until the age of 17.8 years. A total of four dogs were 
followed at stage 2 for a period of 1.8-3.9 years without any signs of 
progression to subsequent disease stages (Study III/Table 2). A total of 
ten dogs showed progression to subsequent disease stages (Study 
III/Table 1). 
ERG revealed a decrease in both rod and cone photoreceptor-
mediated functions at stages 2 and 3 (Study III/Fig. 3). The owners’ 
observations that night-blindness precedes loss of day-vision was 
supported by the ERG indicating that cone function is lost more slowly 
than the rod function. 
An accumulation of autofluorescent material in the subretinal space 
and within the RPE was noted (Study III/Fig. 4E, F). The presence of this 
material was more excessive than is seen with other forms of PRA or in 
normal aging. The acid-fast positive, ceroid/lipofuscin-like material was 
likely to be the source of the red or brown discoloration seen in the tapetal 
fundus at stage 1.  
Other retinal alterations were found in 14 of the studied dogs 
including retinal scars and fold and ‘bull’s eye’ lesions consistent with 
multifocal acquired chorioretinopathy (MAC). Detailed description of other 
unrelated findings can be found in Study III. 
The pedigree suggested a strong genetic contribution (Study III/Fig. 
5). An autosomal recessive mode of inheritance was supported by the lack 
of sex predisposition, and the observation that affected dogs can originate 
from the breeding of non-affected dogs. However, there are litters with 
affected parents but not all offspring develop the disease. This may 
indicate a reduced penetrance or that the offspring have not been 
ophthalmoscopically examined and may in fact be affected. It is also 
possible that the offspring are too young to have developed the clinical 
signs. 
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Figure 13. The Swedish Vallhund is a small spitz-type herding breed with different coat colors 
and a A) bob or B) long tail. C) Normal appearance of the ocular fundus with well-
developed retinal vasculature, and the optic nerve head (arrow) D) Stage 1 is 
characterized by multifocal red/brown discoloration of the tapetal fundus E) In 
Stage 2 signs of degeneration, indicated by multifocal, geographic thinning, are 
present F) In Stage 3 more diffuse retinal thinning is observed as large, bright 
(hyperreflective) regions affecting most of the tapetal fundus. 
A panel of known canine retinal degeneration genes bestrophin 
(BEST1)197-199, cyclic nucleotide gated channel beta 3 (CNGB3)207, 
nephronophthisis 4 (NPHP4)166,167, phosphodiesterase 6B, cGMP-specific, 
rod, beta (PDE6B)72, phosphodiesterase 6A, cGMP-specific, rod, alpha 
(PDE6A)80, and retinal pigment epithelium 65 (RPE65)330 were excluded 
as causative (Study III/Table S3), except for the progressive rod-cone 
degeneration (PRCD)63 because of marker monomorphism, and a genome 
wide approach was initiated to map the disease locus. 
Based on the GWAS, a tentative locus on CFA17 (praw=7.7x10-5, 
pgenome=0.13) was identified (Study IV/Fig. 1A). Genotyping of the SNP 
with the strongest association in a larger replication cohort supported the 
association (prepl=2.7x10-5) (Study IV/Fig. 1A). When analyzing the GWAS 
and replication cohort together, an association significant at a genome-
  
wide level was identified at CFA17 (pcomb =4.3x10-8) with increased risk for 
homozygosity (OR=11.2) (Study IV/Fig. 1A).  
The associated region includes a 6.1 Mb homozygous risk haplotype 
in the cases spanning from 37.5 Mb to 43.60 Mb (Study IV/Fig. 1B). The 
region contains 102 genes, of which anaphase promoting complex subunit 
1 (ANAPC1)331, c-mer proto-oncogene tyrosine kinase (MERTK)332-341 and 
nephronophthisis 1 (NPHP1)342,343 have previously been associated with 
retinal disease or retinal function (Study IV/Fig. 1C). Sequencing the 
coding regions and splice sites revealed three non-synonymous coding 
variants, p.A369P in the MERTK, p.H86R in the NPHP1 and p.V734I in the 
ANAPC1 (Study IV/Table 1).  
The MERTK p.A369P and the ANAPC1 p.V734I variants were 
predicted to be benign while the NPHP1 variant was predicted to be 
pathogenic. The multiple alignments did not support the MERTK or the 
ANAPC1 pathogenecity either. Furthermore, they did not fully segregated 
with the disease in SVs and were present in other unaffected breeds, 
suggesting that they were not causative.   
The targeted resequencing identified altogether 408 SNVs and 70 
indels shared between the SV cases (Study IV/Table S1). Only one 
additional new case specific coding variant, p.L97R, in the lysine-rich 
coiled-coil 1 (KRCC1) gene was found. However, further analysis of this 
variant in additional SVs and in other unaffected breeds did not support its 
segregation with the disease (Study IV/Table 1).  
Among the non-coding variants, 30 were selected across the region. 
The variants were categorized on the basis of their type and position. Non-
synonymous variants were prioritized first, followed by variants in the non-
coding RNAs, UTR regions, and conserved intergenic and intronic regions, 
respectively. No segregation was identified in any of them (Study IV/Table 
2). Possible variations in the CNV and the other repeat regions, SINE and 
LINE, were studied on the basis of a heatmap analysis, but no case 
specific differences were noted in the read depth.  
Based on our analysis of the GWAS and targeted sequencing data the 
SNP, BICF2G630207991, positioned in the intron of MERTK was the most 
strongly associated marker. This marker was further tested in 400 SVs 
revealing a significant risk for homozygosity (p=6.3x10-27, OR=18.5 with 
95%CI=10.3-33.2) and a carrier frequency of 59.9 %.   
Real-time PCR of MERTK, NPHP1, ANAPC1 and KRCC1 revealed a 
6.5-fold upregulation of the MERTK in the affected dogs while no 
difference was found in the other genes (Fig. 14). This result indicates that 
a regulatory mutation outside the coding region results in overexpression 
of MERTK, which leads to retinopathy in the affected dogs. 
MERTK was a highly relevant candidate gene, belonging to the TAM 
receptor tyrosine kinase family, and it has been shown to be expressed in 
the RPE plasma membrane344 and be involved in apoptosis and 
inflammation345. 
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Figure 14. A specific overexpression of MERTK was found in the affected SVs when 
comparing the candidate MERTK, NPHP1, ANAPC1 and KRCC1 genes. The 
relative mRNA expression levels are represented as a fold change. Error bars 
denote the standard error of normalized Ct-values. *p ≤0.0001 (two-tailed t-test p-
value). 
4.4 A novel missense mutation in human Weill-
Marchesani syndrome gene, ADAMTS10, causes 
primary glaucoma in Norwegian Elkhounds (Study 
V) 
The glaucoma phenotype in NEs was described long ago254,255, but 
genetic research has only now become possible with the advent of canine 
genomic tools. To map the disease locus, samples were collected in 
collaboration with ECVO panelists in Finland and the US from 16 affected 
and 596 control dogs. The clinical data of the affected dogs indicated 
bilateral primary glaucoma with significantly elevated IOP, between 25-86 
mmHg (normal 10-20 mmHg) on average, at the age of 6.5 years. In 
addition, various degrees of optic nerve atrophy and cupping with a 
progressive vision loss were seen. Secondary clinical signs included lens 
luxation, corneal stromal edema, Haab´s striae, keratitis, vitreal syneresis 
and retinal degeneration.  
The GWAS revealed a 750 kb locus on CFA20 between at 53.0-53.8 
Mb (praw=4.9x10-6, pgenome=0.03) (Study V/Fig. 2A-C, S2) (Fig. 15). The 
locus is a known canine glaucoma locus, harbouring the known canine 
glaucoma gene ADAMTS10227 (Study V/Fig. 2D), which was selected for 
mutation screening. The gene’s importance was further supported by its 
  
association with glaucoma being consistent with the previously reported 
POAG phenotype of primary glaucoma in NEs254,255.  
 
 
Figure 15. The GWAS mapped the primary glaucoma locus in NEs on CFA20. 
Sequencing the coding regions and splice sites in four affected and five 
control dogs identified altogether ten variants; a non-synonymous variant 
c.1441G>A, p.A387T (Study V/Fig. 3A,B), five synonymous and four non-
coding variants (Study V/Table S3). Only one synonymous variant, 
p.P171P, co-segregated with the non-synonymous variant. However, ESE-
finder did not indicate its position to be in the exonic enhancer region. The 
non-synonymous variant was predicted to be pathogenic, which was 
further supported high evolutionary conservation between 75 species 
(Study V/Fig. S1).  
ADAMTS10 is a secreted glycoprotein346 and belongs to a family of 
metalloproteinases that contribute to the dynamics of the extracellular 
matrix (ECM) composition, microfibril and collagen function and 
remodeling of the membranes247,346-350. It interacts with fibrillin-1 and 
localized to fibrillin-1 microfibril bundles247. 
To gather further evidence for the p.A387T segregation with the 
disease phenotype, seven additional NE primary glaucoma cases, four 
obligatory carriers and 572 randomly selected unaffected NEs were 
genotyped. All but two of the cases were homozygous for the mutation. 
Unfortunately, we had a limited access to the health records and history of 
these two affected dogs and they may have had a secondary glaucoma 
with the primary underlying cause being missed at the end stage of the 
disease. All four obligatory carriers were heterozygous and based on the 
572 NEs a 25.3 % carrier frequency (151/596) was indicated. Only one 
additional homozygous dog was found, which is now 5 years old without 
any signs of glaucoma, but the follow-up needs to be continued. These 
results support the segregation of the mutation in clinically confirmed 
primary glaucoma cases with a highly significant association between the 
mutation and the disease (PFisher=3.5x10-27). The breed-specificity of the 
p.A387T mutation was indicated by its absence in 71 glaucoma or PLD 
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affected dogs from 17 breeds and in 115 unaffected dogs from six other 
breeds (Study V/Table S1). 
  
5 DISCUSSION 
This study focused on four different eye disorders in five different dog 
breeds and made breakthroughs in describing the clinical phenotypes and 
identifying genes and loci for the diseases. It has succeeded in 
establishing remarkable resources for the characterization of canine vision 
disorders and in utilizing the recent genomic tools to map several new 
disease genes. The study demonstrates the feasiblility of mapping genes 
in small populations, while also highlighting the challenges to the 
identification of causative mutations in extensive LD regions in small, 
inbred populations.  
We have clinically described a unique type of retinopathy in the 
Swedish Vallhund and primary closed angle glaucoma in the Dandie 
Dinmont Terrier, neither of which has previously been described in the 
veterinary literature. Furthermore, we mapped three novel genes and a 
novel locus for the studied phenotypes.  
This study is methodologically diverse and utilized various state-of-the-
art approaches to identify the clinical and genetic causes. The study relies 
completely on samples collected from privately owned pet dogs worldwide. 
This required remarkable efforts in collaboration with breeders, breed 
clubs, and dog owners. Overall, thousands of samples from affected dogs 
across various breeds and eye conditions were collected in the DNA bank 
beyond the four phenotypes that were under the specific focus of this 
study. 
An important aspect of this study involves intimate collaborations 
between the basic and clinical research including geneticists and the 
clinicians, both human and veterinary ophthalmologists. This network of 
collaboration enabled us to combine specific expertise in phenotyping and 
sample collection in multiple breeds and conditions utilizing privately 
owned pet populations. This collaboration extended beyond academics to 
dog owners and breeders worldwide who actively participated in the study 
and contributed to the establishment of relevant study cohorts. As a result 
we were able to describe clinically two unreported diseases in SVs and 
DDTs and map or identify the genetic causes. 
Gene mapping relied on the state-of-the-art approaches in the field. We 
used different generations of SNP arrays and the next generation 
sequencing approaches were piloted with the establishment of proper 
bioinformatics analysis pipelines to discover mutations. Although the 
canine reference genome has improved significantly over the years it is 
currently based on the transcript sequences of a limited collection of 
selected tissues not necessarly relevant for this study (for example retinal 
transcripts have not been included). This proved to be one of the major 
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obstacles in this study and prevented comprehensive listing of all the 
possible variants in the target regions for further confirmation. 
This study has several theoretical and practical implications. An 
important observation emerging from these studies identifies the genetic 
similarity of eye disorders across species. Three of the implicated canine 
genes have previously been associated with corresponding phenotypes in 
humans and rodents. In addition, the novel glaucoma locus in DDTs maps 
to a human chromosomal region that has been associated with glaucoma 
in numerous studies and patient cohorts. Moreover, canine genetics 
appear less complex with stronger founder effect with breed-specific traits 
compared with human studies. All affected dogs carry the same mutation 
and do not show significant locus heterogeneity. In contrast, many more 
mutations have been described in the corresponding human phenotypes, 
e.g. altogether six mutations have been found in the human CNGB184,351-
354 and 12 mutations in the human MERTK patients332,334-341,355-358. 
Although we did not find locus heterogeneity in our phenotype, there are 
other PRA breeds with multiple causative loci. For example, PRA in the 
Golden Retriever, consists of at least three genetically different 
types63,62,118. 
Although we were able to define the clinical phenotype and segregation 
pattern of the mutations in most of the affected dogs, some discrepancies 
remain. Some of these can be explained by the age of the dogs, as young 
dogs with the risk genotype may still develop the disease at older age. For 
example, four homozygous dogs were found among Papillons and 
Phalénes without reported signs of retinal degeneration. However, 
additional eye examinations revealed retinal degeneration in two of them, 
while the other two are still quite young for diagnosis. In the NEs, two 
cases without the homozygous mutation were found, suggesting a 
possible secondary disease or other genetic factors. Furthermore, it is 
possible that the observed reduced penetrance may be due to 
environmental factors or epigenetics, especially in SVs and DDTs, as not 
all the affected dogs were homozygous for the risk variant or had the 
phenotype despite having the risk genotype. The clinical follow up of these 
dogs would be of great importance.  
We also observed some breed-specific differences in the phenotype. 
The affected NEs lack severe non-ocular signs that are commonly present 
in the WMS patients. This may be due to a lack of more detailed clinical 
examinations, which need to be carried out in future studies. The genetic 
test allows an early identification of genetically affected dogs that could be 
followed for years for a comprehensive clinical study. 
  
5.1 Clinical and genetic characterization of two canine 
retinal degenerations reveal similarities with 
human retinal disease 
This study describes the clinical and genetic characterization of two retinal 
diseases in Papillon and Phaléne and Swedish Vallhund breeds. The two 
genes implicated for retinal degenerations, cyclic nucleotide gated channel 
beta 1 (CNGB1) in the Papillons and Phalénes and MER proto-oncogene, 
tyrosine kinase (MERTK) in the Swedish Vallhunds are important for 
normal photoreceptor function, especially in rod and RPE cells.  
 In human patients with CNGB1 mutations, several retinal abnormalities 
are reported, some at school age, but more commonly at around 30 years 
of age84,351-354. In a Cngb1-/- mouse model, the gene is important for the 
formation of the rod outer segment CNG channels, and a retinal 
degeneration is diagnosed359. However, the disease in mice progresses 
slowly and 80-90% loss of the rod responses is not detected until the age 
of 1 year360. PRA in Papillons and Phalénes is diagnosed at the middle 
age dogs and progresses similarly to humans and mice, further supporting 
the causative role of the CNGB1.  
CNGB1-dogs provide a new large animal model for potential 
therapeutic purposes. A gene therapy has already been developed for the 
Cngb1-/- mice using AAV-vectors361. The gene therapy resulted in high 
level expression of the CNGB1 protein leading to a delay in retinal 
degeneration and restored rod-driven light responses361. As the AAV-
vector has been shown to work in canine models, a therapy for the 
CNGB1-dogs could be developed in a similar manner. A gene therapy has 
already been developed for the canine CNGB3 gene in a canine model for 
achromatopsia303 and as CNGB1 and CNGB3 are part of the CNG 
channels, the same therapy method may be useful in treating CNGB1-
dogs.  
In SVs, we described clinically a unique, breed-specific form of retinal 
disease with multifocal degeneration of the retina. Other reported retinal 
degenerations typically involve diffuse degeneration of the retina. Other 
specific features in the SV retinopathy include considerable variation in the 
age of onset and rate of progression not known to be present in any other 
breed. Furthermore, another unique detail was the abnormal accumulation 
of autofluorescence material in the RPE. Clinical observation and 
histopathological evaluation confirmed that the disease affects both 
photoreceptors and the RPE. However, the primary defective cell 
population cannot be determined with the limited material available. The 
discrepancies noted with respect to the rate of disease progression among 
Swedish Vallhund dogs suggest that genetic or environmental disease 
modifiers are likely to play a role in the pathogenesis. Retinal function is 
modified by environmental factors60,362-364 and we investigated the role of 
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vitamin-E deficiency, but the results were inconclusive to in regard to the 
correlation with the clinical variability. 
The SV retinopathy appears clinically and genetically unique. While 
other retinal degenerations are often shared at least among related 
breeds60,362-364, the SV retinopathy has not been described in any other 
breed and the MERTK locus was also mapped for the first time for canine 
retinal degeneration. It is possible that this relatively old breed originating 
from the Viking era between 8th to late 11th century has avoided mixing 
with other breeds, although Welsh Corgis may be created from SVs, 
according to the Swedish Vallhund breed club.  
Although the actual causative mutation remains to be found, MERTK 
stood out as the most likely candidate gene based on its function and 
clinical significance in the retinal degeneration in other species333,337,339,355. 
Furthermore, we were able to show that the gene is upregulated in the 
affected SVs, indicating the presence of regulatory mutation. The 
upregulation was MERTK specific as no changes in expression levels of 
other candicate gene was found.  
In human, mutations in MERTK have been associated with several 
recessive phenotypes332,334-336,340,341,355-358,365-369. Moreover, it has been 
shown that human patients show deposit of autofluorescence material, 
which may represent photoreceptor outer segment membranes, including 
lipofuscin, over-accumulating in the outer retina339,357.   
Besides human, MERTK has been extensively studied in the Royal 
College of Surgeon (RCS) rats333,370. The rats present a progressive loss 
of photoreceptor cells due to abnormal phagocytosis of photoreceptor 
outer segments that normally should occur by the RPE333. This leads to 
the accumulation of photoreceptor outer segment (POS) debris between 
photoreceptors and the RPE370-373. Human and rat models have been 
associated with recessive loss-of-function mutations while our canine 
model represent a gain-of-function model with overexpression of the 
MERTK gene.  
Although, we were not able to pinpoint the actual causative mutation, 
it is probable that the causative mutation is in LD with the identified 
marker, and the same carrier frequency might be seen also if the actual 
mutation was tested. However, the affected dogs present a novel model 
for the role of MERTK in the retinal biology. Whole genome sequencing 
might be considered in order to reveal the causative mutation. WGS has 
an advantage over the capture protocols as it does not exclude repetitive 
regions, which could be causal.  
  
5.2 Canine glaucoma studies reveal a known human 
gene and a new candidate locus 
This study describes the clinical and genetic characterization of primary 
closed and open angle glaucomas in the Dandie Dinmont Terrier and 
Norwegian Elkhound breeds, respectively. The ADAMTS10 mapped in 
NEs has previously been associated with the canine POAG and is 
important in the glaucoma pathogenesis. Furthermore the CFA8 locus in 
DDTs is syntenic to human chromosome 14 containing multiple glaucoma 
loci. These genes and loci have been implicated in similar phenotypes in 
humans and rodents. 
In DDTs, the clinical study revealed that the phenotype mainly 
resembles PACG with an onset at the middle age. This was the first study 
to describe the DDT phenotype in detail. However, the actual onset is 
likely to be earlier as most of the affected dogs visit a veterinary clinic at a 
later stage of the disease and initial clinical signs may have gone 
unnoticed. Congenital disease cannot be formally ruled out.  
In DDTs a novel locus was mapped on CFA8 and was found to support 
a recessive inheritance mode, possibly with reduced penetrance. 
However, no causative variant was identified in any of the candidate 
genes. This locus is the second mapped canine glaucoma locus in 
addition to the Beagle locus on CFA20 with the ADAMTS10 mutation227. 
More recently, two loci have been suggested in the Basset Hound on 
CFA14 and CFA24 near the genes COL1A2, PEG10 and RAB22A, 
respectively229. However, the association signals were only tentative, 
suggesting too small a sample size, or too complex a phenotype, to reach 
the genome wide significance level, and no functional variant was found in 
the studied genes. In contrast, the CFA8 locus is strongly supported by the 
genetic data in our study.  
Another glaucoma study was published in the Shih Tzu and Shiba Inu, 
in which three candidate genes were studied by genotyping SNP 
markers228. A significant association was found for the SRBD1 gene, with 
two significant markers, a synonymous and an intronic SNP, which may 
serve as markers to evaluate the development of glaucoma in these two 
breed. SRBD1 is located on CFA10, but outside our association signal, 
excluding the role of SRBD1 in the DDT glaucoma. 
The mapped DDT PACG locus shares synteny with a region on human 
chromosome 14. Chromosome 14 has been associated several times in 
human PCGs and POAG283,374-378, but not PACG. None of the human 
PCG or POAG loci on chr14 directly overlap with the canine locus mapped 
in DDTs. However, our data suggest a novel locus within the same 
glaucoma cluster for further studies in human cohorts. 
In Norwegian Elkhounds a mutation in the ADAMTS10 was found 
causative in primary glaucoma. The GWAS mapped the locus on CFA20 
harbouring the ADAMTS10 gene. The missense mutation in the NEs is 
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located in the metalloprotease domain and this may indicate that the 
pathogenesis of the primary glaucoma in NEs is different from the Beagle, 
as the p.G661R mutation is situated in the cysteine rich domain and is 
hypothesized to disrupt protein folding leading to instability227. The NE 
mutation changes a highly conserved residue in the metalloprotease 
domain, which plays a role in the remodeling of the connective tissue379.   
In human, mutations in the metalloprotease domain lead to 
abnormalities in the cellular cytoskeleton. This may be due to abnormal 
interactions with the ECM379. Lens ligaments are comprised primarily of 
fibrillin-1 and the lens is maintained in its position by lens ligaments248. 
Fibrillin-1 is expressed in the outflow pathway of the aqueous humor and 
defect in it may lead to impaired aqueous humor flow249-251. The 
cytoskeleton abnormalities may result in defective microfibrils and 
glaucoma through fibrillin-1. Unfortunately, we did not have access to any 
tissue samples from the affected dogs to further investigate the functional 
consequences of the mutation for ADAMTS10 and its pathway. Secondary 
lens luxation diagnosed in the affected NEs may be due to abnormal 
fibrillin-1 function as the ADAMTS10 and fibrillin-1 interaction may be 
impaired causing disruption of the lens ligaments.  
In humans, mutations in ADAMTS10379,380, ADAMTS17380, and in 
fibrillin 1 (FBN1)381 have been associated with Weill-Marchesani syndrome 
(WMS) (OMIM 277600). WMS is a connective tissue disorder and 
characterized by several eye defects and other skeletal features382. 
Ectopia lentis is the most prevalent ocular defect though glaucoma is also 
diagnosed383.   
Fibrillin-1 defects are thought to cause dysgenesis of the lens 
ligaments and ectopia lentis247. In dogs mutation in the ADAMTS17 has 
been shown to cause ectopia lentis in multiple different breeds384. The 
ectopia lentis in dogs is probably caused by the fibrillin-1 defect as 
ADAMTS17 and ADAMTS10 are important for normal fibrillin 
function227,384,385. However, none of the affected NE dogs had any signs of 
primary lens luxation, although this should be expected based on 
importance of ADAMTS10 and fibrillin connection. Access to tissue 
samples and histological analyses may give new insight into the possible 
lens zonular dysplasia in NEs. 
Furthermore, therapy trials could be developed for NEs, although this 
might be problematic due to the late-onset of the disease. However, NEs 
provide a second large animal model, in addition to the Beagle, to study 
the ADAMTS10 pathogenesis, its role in glaucoma and how fibrillins may 
influence the glaucoma development.  
  
5.3 New tools and models for therapeutic trials, 
breeding programs and veterinary diagnostics  
This study has also several practical implications that have positive effects 
on breeding programs and veterinary diagnostics. First, two gene tests 
have already been developed for Papillons and Phalénes and NEs to help 
the breeders to avoid affected dogs. In both conditions, the carrier 
frequencies were high, 17 % and 25 %, respectively and the genetic tests 
can be utilized to eradicate the diseases in the breeds without 
compromising the breeds’ genetic diversity by keeping the unaffected 
carrier dogs in the breeding populations.  
Second, a marker based test can be developed for SVs while waiting 
for the discovery of the causative mutation. The prevalence of the SV 
retinopathy was almost 35 % and the carrier frequency for the best marker 
close to 60 %. For DDTs, the development of a marker test is more 
problematic. Although the risk for homozygous dogs was high (32-fold, 
with 95% C.I. 3.7-280.8), the breed is very small worldwide and largely 
affected with PLD in addition to glaucoma. Removing dogs from the 
breeding programs based on such high C.I. may be more harmful for the 
breed than allowing homozygous risk dogs. Importantly, it would be of 
great significance to identify the actual causative mutation to increase 
accuracy of the test and risk models in the DDT population.  
High risk allele frequencies pose a challenge for the breeding programs 
as carrier-carrier matings cannot be avoided without compromising too 
much of the genetic diversity of the breeds. In SVs, it might be worth 
considering mixing the breed with other breeds to increase diversity and to 
reduce the frequency of the risk allele. This study demonstrates the harsh 
reality about the genetic structure of the breeds with extremely high-risk 
allele carrier frequencies, which may be impossible to eradicate from the 
breed without major changes in the breeding plans. New recessive 
diseases might become more frequent in the breed if too many carrier 
dogs are removed from breeding pools. It is also worth noting that there 
could be some differences in the accuracy of the marker and mutation 
tests, although canine LD is extensive.  
Third, the genetic tests developed on the basis of this study can also 
be used as a part of the veterinary diagnostics to distinguish the 
genetically known diseases from each other and to test unknown 
conditions for the inclusion or exclusion of the gene. For example, PRA 
tests developed from this study could be utilized in differential diagnoses 
to distinguish genetically different PRAs commonly present in many 
breeds. This study has shown the benefits of the dog as a large animal 
model in genetic research. It has provided new tools for breeding and 
novel theraputical models for medical research in humans. Furthermore 
building a collaboration network between genetics and clinicians has been 
a vital part of this study. 
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6 CONCLUSIONS AND FUTURE PROSPECTS 
This study reveals significant new insights into the two of the most 
common hereditary ocular diseases causing blindness, retinal 
degeneration and glaucoma. The diseases are diagnosed in both humans 
and dogs and have an effect on the quality of life for humans while in dogs 
the diseases cause significant burden for the affected dogs and the dog 
owners. Irreversible blindness is the end point of the disease and no 
known cure exists at the moment for either disease. In addition, glaucoma 
is a painful disorder, if IOP is significantly elevated. 
Furthermore, this study shows the benefits of the dog as an animal 
model. Instead of laboratory colonies, only privately owned pet dogs were 
used in this study. No affected dogs were bred for study purposes. The 
unique canine population structure facilitates genetic studies and 
substantial breakthroughs are possible in small sample cohorts. However, 
this necessitates efficient collaboration with breeders and private 
veterinarians. Based on the result two gene and one marker test have 
been developed. To best describe the significance of this study to the dog 
owners, a NE breeder wrote:  
“I would like to thank you and your team from the bottom of my heart for  
doing this research. Back in the 1980s I had a bitch who developed  
glaucoma at 2 years old. She was totally blind by 4 years old and  
although she lived a happy life to 13, it was absolutely devastating for  
all of us. Her grandsire on the dam's side was a Norwegian import, who 
himself had glaucoma so I now know that  
her sire must have also carried the gene. All we could  
do back then was avoid using that dog again. New breeders now don't  
remember those cases so the importance of finding out about glaucoma 
has  
become less to them. This research will mean that no dog and no owner  
should ever have to suffer like our dog did and we did. Once again thank 
you for all your hard work. I've lived with two dogs with glaucoma and 
never thought I would see this day. I am so thrilled.” 
 
This illustrates the importance of studying diseases among pet 
populations. The gene tests can now be used to help with the breeding 
and to avoid affected dogs. Furthermore, the carriers can be used in 
breeding programs to maintain the genetic diversity in the breed.  
Collectively, these results give new insight into molecular pathways in 
retinal degeneration and glaucoma in dogs and show the power of dogs in 
genetic research of ophthalmological diseases. Our results implicate two 
retinal genes in the conditions and establish the affected breeds as 
potential models for gene therapy trials. The novel glaucoma locus in 
DTTs may also contain a yet unknown gene for human glaucoma, 
  
advancing the understanding and treatment of the conditions in both 
species. 
The identification of genes causative for canine vision disorders will 
also enable comparative studies across species, including humans, as all 
studied phenotypes are diagnosed in human patients. This study is likely 
to benefit the human medical research and possibly aid the development 
of new therapy methods.  
While gene mapping is feasible in canine population, this study 
demonstrates also the challenge of extensive LD for the identification of a 
mutation in gene rich regions. Despite extensive efforts with state-of-the-
art approaches, we could not find the mutation in the identified regions for 
two phenotypes. Therefore, two important major tasks remain in this study: 
the identification of the causative mutations for retinal degeneration in SVs 
and PACG in DDTs. Further studies into retinal degeneration of SVs 
should include the analysis of the retinal transcripts in affected and 
unaffected SVs. The aim is to obtain more detailed information on the 
retinal genes in a normal retina and to study the possible alterations 
between affected and unaffected SVs. As for DDTs, our existing targeted 
NGS data needs to be reanalyzed using the new canine reference 
sequence and annotation to identify the causative variant.  
Other interesting studies would include further clinical studies in the NE 
glaucoma to investigate whether additional ocular or non-ocular 
abnormalities are present. For example, the lenses of the affected dogs 
should be followed to obtain information on possible signs of lens luxation. 
This would provide information on possible species-specific differences in 
the gene function and genotype-phenotype correlations of the mutations 
between dogs and humans.  
Importantly, during this study a significant canine DNA bank was 
created holding thousands of samples from tens of different ocular 
phenotypes. This remarkable resource will benefit ongoing and future 
genetic studies in canine vision disorders to reveal new insights into the 
ocular and other diseases diagnosed in the man´s best friend. 
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